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ABSTRACT 
Normal tissues are organized in a hierarchical fashion, where rare somatic cells 
endowed with stem-like properties give origin to a population of differentiated cells 
forming the bulk of tissue. These self-maintaining cells, called stem cells, are 
characterized by 4 fundamental properties: longevity, multipotency, quiescence, and 
asymmetric cell division.  
We decided to develop a new in vitro system for separation of stem-like 
epithelial cell based not on surface marker-driven selection, but by simply taking 
advantage of their slow proliferation rate in the absence of serum.  
Dissociated colonic epithelial cells were stained with PKH26, which allows 
identification of distinct populations based on their proliferation rate, and cultured in 
vitro in the absence of serum. The cytofluorimetric expression of CK20, Msi-1 and 
Lgr5 was studied. The mRNA levels of several stemness-associated genes were also 
compared in cultured cell populations and in three colon crypt populations isolated 
by microdissection. A PKH
pos
 population survived in culture and formed spheroids; 
this population included subsets with slow (PKH
high
) and rapid (PKH
low
) replicative 
rates. Molecular analysis revealed higher mRNA levels of both Msi-1 and Lgr5 in 
PKH
high
 cells; by cytofluorimetric analysis, Msi-1
+
/Lgr5
+
 cells were only found 
within PKH
high
 cells, whereas Msi-1
+
/Lgr5
-
 cells were also observed in the PKH
low
 
population. As judged by qRT-PCR analysis, the expression of several stemness-
associated markers (Bmi-1, EphB2, EpCAM, ALDH1) was highly enriched in Msi-
1
+
/Lgr5
+
 cells. While CK20 expression was mainly found in PKH
low
 and PKH
neg
 
cells, a small PKH
high
 subset co-expressed both CK20 and Msi-1, but not Lgr5; cells 
with these properties also expressed Mucin-1, and could be identified in vivo in colon 
crypts. These results mirrored those found in cells isolated from different crypt 
portions by microdissection, and based on proliferation rates and marker expression 
they allowed to define a hierarchy of cellular subsets at different maturation stages: 
PKH
high
/Lgr5
+
/Msi-1
+
/CK20
-
, PKH
high
/Lgr5
-
/Msi-1
+
/CK20
+
, PKH
low
/Lgr5
-
/Msi-
1
+
/Ck20
-
, and PKH
low
/ Lgr5
-
/Msi-1
-
/ CK20
+
 cells. 
We next addressed the issue of cancer stem cells in colorectal cancer (CRC). 
Isolated cells from five primary colon tumors and 15 CRC metastatic samples were 
stained with PKH26 and cultured in PhEMA-treated plate in the absence of serum. 
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As in normal samples, in tumors we identified a slowly cycling population able to 
persist in vitro in serum-free condition. On the contrary, in metastatic samples we 
could not document an in vitro selection of a PKH
high
 population; actually PKH
low
 
cells seemed to remain constant over several weeks. Cytofluorimetric analysis 
revealed that, at variance with normal samples, in metastatic samples Lgr5
+
/Msi-1
+ 
cells were not only present in the slowly cycling PKH
high
 population but also in 
PKH
low 
cells. No Lgr5 or Msi-1 expression was recorded in PKH
neg
 cells. Both 
PKH
high
 and PKH
low
 cells were able to form spheroids; in the presence of 10% FCS 
in uncoated plates they adhered to the plate and differentiated assuming an epithelial 
morphology. They eventually lost Msi-1 and Lgr5 expression after 14 days of culture 
in the presence of serum and adhesion conditions, and they also acquired CK20 
expression.  
Finally, we investigated the possible involvement of Notch signaling on 
regulation of Msi-1 levels in the metastatic cell line MICOL-14
tum
 and primary 
metastatic samples. Seventy two hours of treatment with the Notch ligand DLL4 
increased Msi-1 mRNA and protein levels. This phenomenon was largely prevented 
by the addition of an antibody neutralizing Notch2/3, whereas no reduction was 
detected after incubation with -Notch1. Since Msi-1 regulates Numb levels, its 
reduction led to increased Numb protein, as demonstrated by Western Blot analysis 
of MICOL-14
tum
 and primary metastatic cells. Furthermore, after four days of 
treatment, formation of spheroids was significantly reduced by incubation with -
Notch2/3 antibody in primary samples as well as in MICOL-14
tum
 cells. 
In conclusion, our data showed the possibility of deriving in vitro from normal 
colon tissue, without any selection strategy, an array of cellular subsets differentially 
expressing the most common stemness and differentiation markers of human colon 
epithelial cells, which recapitulate the phenotypic and molecular profile of cells in an 
anatomical position compatible with stem-like cells.  
Furthermore in metastatic cell line and primary samples we described a novel 
feed-forward circuit involving Msi-1, Numb, Notch3 and Notch1. In particular, we 
demonstrated that Msi-1 could be considered a target of Notch3, and Notch3 could 
act as a positive regulator of Notch1 levels through Msi-1/Numb circuit.  
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RIASSUNTO 
 
I tessuti normali non patologici sono organizzati in una struttura gerarchica 
all'interno della quale un numero esiguo di cellule origina l'intera totalità della 
popolazione. Queste cellule presentano longevità, multipotenza, quiescenza e 
capacità di dividersi in maniera asimmetrica, tutte caratteristiche di staminalità.  
Abbiamo deciso di sviluppare un sistema in vitro per separare le cellule staminali 
epiteliali del colon, non basandoci sull'espressione di specifici marcatori di 
superficie, ma semplicemente traendo vantaggio dal ridotto tasso di proliferazione 
che queste cellule presentano quando tenute in assenza di siero. 
Da campioni primari di colon le cellule epiteliali sono state dissociate, marcate 
con PKH26, che permette l'identificazione di distinte sottopopolazioni basandosi sul 
tasso di proliferazione, e coltivate in vitro in assenza di siero. Sono stati analizzati i 
livelli di espressione proteica di CK20, Msi-1 e Lgr5 e di mRNA di alcuni geni 
associati alla staminalità. L'espressione di questi geni è stata confrontata tra la 
popolazione cellulare in cultura e tre sottopopolazioni isolate dalle cripte di colon 
attraverso microdissezione laser. 
In coltura abbiamo identificato una popolazione PKH
pos
, in grado di sopravvivere 
e formare sferoidi, comprendente cellule con un ridotto tasso di proliferazione 
(PKH
high
) e cellule con rapido tasso (PKH
low
). L'analisi citofluorimetrica ha 
dimostrato che cellule Msi-1
+
/Lgr5
+
 si trovano solo nella popolazione PKH
high
, 
mentre cellule Msi-1
+
/Lgr5
- 
sono presenti anche nella popolazione PKH
low
. Questi 
risultati sono stati supportati dall'analisi molecolare nelle diverse sottopopolazioni. 
Nelle cellule Msi-1
+
/Lgr5
+
 abbiamo, infatti, riscontrato livelli più alti di espressione 
di geni associati con la staminalità (Bmi-1, EphB2, EpCAM, ALDH1). Invece 
l'espressione di citocheratina (CK20) è quasi totalmente ristretta alle cellule PKH
low
 e 
PKH
neg
, le quali esprimono anche Mucin-1 ma non Lgr5. 
Questi risultati rispecchiano quelli trovati analizzando le popolazioni isolate dalle 
diverse porzioni delle cripte attraverso microdissezione, e ci hanno permesso di 
definire una gerarchia di sottopopolazioni cellulari diverse in differenti fasi di 
maturazione: PKH
high
/Lgr5
+
/Msi-1
+
/CK20
-
, PKH
high
/Lgr5
-
/Msi-1
+
/CK20
+
, 
PKH
low
/Lgr5
-
/Msi-1
+
/Ck20
-
, e PKH
low
/ Lgr5
-
/Msi-1
-
/ CK20
+
. 
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Per valutare la presenza di diverse sottopopolazioni con caratteristiche di 
staminalità anche nel tessuto tumorale, da 5 campioni di tumore primario colorettale 
e da 15 di metastasi, abbiamo isolato le cellule, marcate con PKH26 e mantenute in 
assenza di siero. Come per i campioni normali, nei tumori abbiamo identificato una 
popolazione cellulare poco proliferante e in grado di sopravvivere in vitro in assenza 
di siero. Invece, nei campioni metastatici non siamo stati in grado di definire 
chiaramente una popolazione PKH
high
; sembra, infatti, che siano le cellule PKH
low
 in 
grado di sopravvivere più a lungo in cultura e quindi selezionarsi. 
L'analisi citofluorimetrica ha dimostrato che, a differenza dei campioni normali, 
in quelli metastatici cellule Lgr5
+
/Msi-1
+
 non sono presenti solo nella popolazione 
PKH
high
, ma anche all'interno della sottopopolazione PKH
low
. Nelle cellule PKH
neg
 
invece non si riscontra l'espressione nè di Lgr5 nè di Msi-1. Entrambe le popolazioni 
PKH
high
 e PKH
low
 sono state in grado di formare sferoidi e, quando mantenute in 
presenza del 10% di siero, hanno aderito alle piastre differenziandosi ed assumendo 
una morfologia epiteliale. Queste cellule perdono conseguentemente l'espressione di 
Msi-1 e Lgr5 solo dopo 14 giorni in queste condizioni, mentre acquistano 
l'espressione di CK20. 
Vista la ridotta presenza di dati inerenti la regolazione di Msi-1, abbiamo infine 
indagato il possibile coinvolgimento del pathway di Notch sulla regolazione di Msi-1 
nelle cellule di tumore del coloretto. Dopo 72 ore di trattamento con il ligando di 
Notch (DLL4) i livelli di proteina e mRNA di Msi-1 aumentano. Questo fenomeno è 
bloccato dall'aggiunta di un anticorpo neutralizzante Notch2/3, mentre nessuna 
variazione è stata riscontrata dopo il trattamento con -Notch1. Poiché Msi-1 regola 
i livelli di Numb, la sua diminuzione comporta un aumento dei livelli proteici di 
Numb, come riscontrato dall'analisi Western Blot effettuata nei campioni tumorali 
primari e nella linea cellulare MICOL-14
tum
. Inoltre, dopo quattro giorni di 
trattamento, la formazione di sferoidi appare significativamente ridotta dal 
trattamento con -Notch2/3. 
In conclusione, i nostri dati dimostrano la possibilità di derivare in vitro da 
campioni di colon normale, senza alcuna strategia selettiva, delle sottopopolazioni in 
differenti fasi di maturazione. Inoltre, nel tessuto metastatico siamo stati in grado di 
descrivere un possibile circuito di regolazione che coinvolge Msi-1, Numb, Notch3 e 
Notch1. In particolare, abbiamo dimostrato che Msi-1 può esser considerato un target 
 5 
di Notch3, e Notch3 può agire come un regolatore positivo di Notch1 attraverso il 
circuito Msi-1/Numb.  
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INTRODUCTION 
 
1. NORMAL STEM CELLS 
1.1 Features 
Stem cells (SC) are undifferentiated cells destined to replenish the pool of mature 
cells whenever needed; for instance, they start to differentiate in response to specific 
stimuli such as injury. Based on their ability to differentiate, SC are classified as 
totipotent (cells able to give rise to a new individual i.e. embryonic SC), 
pluripotent (cells able to give rise to almost all tissues of the body), or multipotent 
(cells able to generate more cell types on a certain location or single histotype) [1]. In 
the last group we enclose adult SC, whose main function is tissue homeostasis and 
repair after injury [2]. Adult SC are cells characterized by three distinct properties: 
1) prolonged lifespan  
2) ability to self-renewal  
3) potential to generate all the differentiated populations within the tissue in which 
they reside. 
Besides longevity and multipotency, another feature commonly attributed to stem 
cells is a relative quiescence. In fact, although residing in most rapidly renewing 
tissues such as intestine or stomach, SC are supposed to divide infrequently, and, 
when they do not divide, they are able to enter in a quiescent state (G0) of the cell 
cycle [3]. At variance with non-SC, when proliferating, SC can undergo asymmetric 
division, eventually producing one rapidly cycling cell and another that replaces the 
parental stem cell. The rapidly cycling daughter cells, also called transit-amplifying 
cells (TA), are responsible for replacing damaged or exfoliated tissues. TA cells 
typically undergo a limited number of cell divisions, after which they terminally 
differentiate. 
As depicted in Figure 1, adult SC can potentially follow 3 models of cell 
division: symmetric division to generate two cells with stem phenotype, asymmetric 
division giving rise to two types of cells (daughter cell with the same stem properties 
and dividing potential, and a progenitor TA cell which has limited proliferation 
potential) or symmetric division to generate two daughter TA cells.  
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Figure1. Adult SC–driven tissue-renewal in colon. (A) Stem cells concomitantly self-
renew and generate rapidly dividing TA daughter cells via asymmetric cell division. The TA 
cells undergo several rounds of division before differentiating into the mature, functional cell 
types of the adult tissue; (B) Three models of cell division: two symmetric and one 
asymmetric division [4]. 
 
In adults, SC reside in a physiologically limited and specialized 
microenvironment, called niche, that supports SC but varies in nature and location 
depending on the tissue type [5, 6]. Remarkable progress has been made in studies 
regarding the interaction between SC and their surrounding microenvironment in 
flies, Caenorhabditis elegans, and mammals. By comparing the SC niches in these 
systems, have emerged features and functions common to all [7]:  
 The niche is composed of a group of cells in a special location that functions 
to maintain SC. 
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 The niche is a physical anchoring site for SC, and adhesion molecules are 
involved in the interaction between SC and the niche and between SC and the 
extracellular matrix.  
 The niche generates extrinsic factors that control SC number, proliferation, 
and fate determination. Many developmental regulatory signal molecules, 
including Wnt, bone morphogenetic proteins (BMP), fibroblast growth 
factors (FGF), and Notch, have been shown to play roles in controlling SCl 
self-renewal and in regulating lineage fate in different systems.  
 The niche controls normal asymmetrical division of SC.  
Normally, at least in the hematopoietic, intestinal, and hair follicle systems, the niche 
maintains SC primarily in a quiescent state by providing signals that inhibit cell 
proliferation and growth [8]. Only upon receipt of a stimulating signal, SC become 
activated to divide and proliferate. Therefore, SC proliferation depends on dynamic 
niche signaling. Maintaining a balance between proliferation and anti-proliferation 
signals is the key to homeostatic regulation of SC, allowing them to undergo self-
renewal while supporting ongoing tissue regeneration [9].  
To identify the SC compartment was initially used Bromodeoxyuridine (BrdU) 
labeling, based on the assumption that SC divide infrequently and retain the DNA 
label for longer than the more rapidly cycling progenitor cells. This method was 
subsequently replaced by the identification of specific markers and the evaluation of 
the in vitro ability of SC to form rounded structures when cultivated in specific 
conditions. These structures have been named Sferoids; depending of the tissue of 
origin, it is possible to identify colonspheres (from colon), mammospheres (from 
mammary gland tissue), pneumospheres (lung tissue), neurospheres (from brain 
tissue) and so on. To date, many protocols have been described to produce in vitro 
spheroids from SC. The most common technique exploits SC embedding into a 
Matrigel compound that mimic the niche support. Otherwise it is possible to culture 
SC on non-adhesive surface such as coated plates that prevent adhesion, permitting 
SC to float in the medium (i.e. collagene or Poly 2-hydroxyethyl methacrylate-coated 
plates). Very recently, Sato et al. [10] and Jung et al. [11] first succeeded in isolating 
and expanding in vitro normal human colonic stem cells by an experimental protocol 
which entailed the use of a complex combination of several growth factors [10] and a 
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positive selection strategy based on the expression of the Ephrin type-B receptor 2 
(EphB2) [11]. Thanks to this protocol, a single stem cell was able to form 
multicellular structures called organoids, since they presented crypt domains 
surrounding a central lumen lined by a villus-like epithelium (‘villus domain’). 
 
1.2 Colon Stem Cells 
The large intestine comprises the ascending colon, transverse colon, descending 
colon, sigmoid colon, rectum and anal canal. In general, the colon wall is composed 
of four histologically distinct layers; from inside to outside there are the mucosa, 
submucosa, muscolaris externa (muscle layer) and serosa. The innermost layer 
consists of a mucosa that includes the epithelium, lamina propria, and a thin layer of 
muscle (Figure 2). The simple columnar epithelium is folded to form a number of 
invaginations embedded in the connective tissue. These test-tube-shaped structures, 
called crypts of Lieberkühn, and containing approximately 2000–3000 cells/each 
[12], represent the functional unit of the colon involved in the absorption of water 
and vitamins. 
The entire colon contains millions of self-renewing crypts, and it has been 
estimated that over 6x10
14
 epithelial cells are produced during the lifetime of an 
individual.  
       
 
Figure 2: Colon structure. Anatomical components (left) and histology (right) of the colon 
[13]. 
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The colon is organized in a hierarchical fashion and the epithelial layer is totally 
renewed every 5 days in humans [14]. The compartment of pluripotent stem cells is 
located at the crypt bases. The colon SC show unique properties as they remain in an 
undifferentiated state and produce epithelial cells that are committed to three 
different cell lineages within the colonic crypt compartment: goblet cells, 
enteroendocrine cells and enterocytes. The mucous-secreting goblet and the 
peptide hormone-secreting enteroendocrine cells belong to the secretory lineage 
whereas the enterocytes are members of the absorptive lineage.  
SC usually give rise to two different daughter cells by asymmetric division to 
maintain normal crypt size and homeostasis [15]. After division, the daughter SC 
remains at the bottom of the crypt for guarantee self-renewal while the other is 
committed to TA status and start to migrate along the crypt wall to terminally 
differentiate at the crypt apex (Figure 3).  
 
Figura 3. Colon crypt organization. Schematic representation of different cell population 
distribution along colon crypt. SC reside at the crypt bottom where they communicate with 
the niche cells - the pericryptal myofibroblasts. When in division, SC produce TA cells that 
start to migrate along the crypt wall to reach the apex once terminally differentiated [16]. 
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1.3 Colon SC markers 
In colon tissue, thanks to its architectural structure, the identification of putative 
SC markers has been favored by SC location at the bottom of the crypt. 
Fujimoto and colleagues identified the integrin subunit 1 (CD29) as a candidate 
marker for the proliferative zone of the human colonic crypt, which includes SC and 
progenitor cells [17]. They demonstrated that the cells located in the lower third of 
the crypt expressed higher levels of CD29, compared to the cells in the remainder of 
the crypt.  
A new marker for colon SC was identified in the Aldehyde Dehydrogenase 1 
(ALDH1) enzyme. ALDH is a detoxifying enzyme that oxidizes intracellular 
aldehydes, thereby confering resistance to alkylating agents [18]. In fact, the 
detoxification capacity of ALDH, by protecting SC against oxidative insult, might 
underlie the well-recognized longevity of SC. ALDH also converts retinol to retinoic 
acid, a modulator of cell proliferation, which may also modulate SC proliferation. 
Immunostaining of human colon crypts showed that ALDH1
+
 cells were confined to 
the crypt bottom, where SC are thought to reside [19].  
The hyaluronic acid receptor CD44 was also used in combination with the 
epithelial marker epidermal surface antigen (ESA) to identify and isolate colon SC. 
However, immunohistochemical analysis of normal colonic epithelium showed that 
CD44 expression occurred not only in cells at the crypt bottom, but also in cells 
within the proliferative compartment, where rapidly proliferating cells reside [20]. 
Another molecule identified as a putative human colon SC marker was Musashi-
1 (Msi-1); Nishimura and his group demonstrated that only some cells at the crypt 
bottom expressed this marker [21]. Recently dublecortin CaM kinase-like-1 
(DCAMKL-1), a microtubule-associated kinase expressed in postmitotic neurons, 
has been proposed as a putative colonic SC marker [22]. DCAMKL-1
 
was found 
expressed in the same cells as Msi-1, but likely represented a subset of Msi-1-
expressing cells. In particular, DCAMKL-1
+
 cells were found to be apoptosis-
resistant following radiation injury.  
B-lymphoma Mo-MLV insertion region 1 (Bmi-1) is a Polycomb Group (PcG) 
protein identified as an oncogene that regulates cell proliferation and transformation, 
and plays an important role in hematopoiesis and development of nervous systems. 
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Bmi-1 was first identified as small intestine SC marker and subsequently proposed as 
a colon SC marker [23]. 
In 2007 Barker and his colleagues [24] proposed Leucine-rich repeat-containing 
G protein-coupled receptor 5-positive (Lgr5) protein to define colon SC. This 
protein was first identified in mouse small intestine, where a single Lgr5
+
 cell was 
demonstrated to be able to regenerate a complete crypt-like structure in vitro (in 
Matrigel support). Barker and his colleagues also demonstrated that each crypt 
contains approximately six long-lived stem cells intermingled with goblet cells in 
colon. Counter-intuitively, these cells were not quiescent, but divide every day. Their 
daughter cells constitute the TA crypt compartment that divides every 12–16 h, 
generating more or less 300 cells per crypt every 6 day. They reside within crypts for 
approximately 48 h, undergoing up to five rounds of cell division while migrating 
upwards. During the differentiation process, the committed TA cells reach the crypt 
apex, where they rapidly die as totally differentiated cells [25].  
Thus, despite that several colon SC markers have been recognized, it is as yet 
impossible to define a specific phenotype for colon SC: depending on the techniques 
used for SC isolation, culture and analysis, and depending on the surface marker 
used, the percentage of SC in human colon samples ranges from 0.1 to 10%.  
Furthermore, according to the different marker expression it seems that two different 
populations of SC could be recognized: a SC compartment in a quiescent state (i.e. 
DCAMKL-1
+
 cells) and an actively cycling population (i.e. Lgr5
+
 cells also called 
Crypt Basal Columnar (CBC) cells.  
 
Marker Other name Function References 
CD29 Integrin b1 Cell adhesion molecule 17 
ALDH1 ALDC Enzyme 18, 19 
CD44 CDW44 Cell adhesion molecule, 
Hyaluronic acid receptor 
20 
Lgr5 GPR49 Unknown, Wnt target gene 24, 25 
Msi-1  RNA binding protein 21 
DCAMKL-1  Kinase 22 
Bmi-1  Transcript repressor 23 
 
Table1. Normal colon SC markers. List of SC markers identified in human normal colon 
tissue. 
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1.4 Musashi-1  
Among the different colon SC markers, Musashi-1 (Msi-1) looks as the most 
interesting and promising marker. Msi-1 is a RNA-binding protein initially 
recognized as a protein required for asymmetric divisions of sensory organ precursor 
cells in Drosophila [26]. The name Musashi is a tribute to the famous 17
th
 century 
Samurai, Miyamoto Musashi, who developed the two swords technique that recalls 
Msi-1 three-dimensional structure. 
Through immunohistochemical analysis Msi-1 expression has been observed in 
neural precursor cells of the developing central nervous system (CNS). In 1998 it 
was recognized as a marker for stem cells of the CNS, while only in the 2003 
Nishimura and colleagues [21] demonstrated that the expression of Msi-1 in normal 
colon mucosa was restricted to the lower part of the crypt, where bona fide stem cells 
reside. In the next years Msi-1 has been described as a marker of adult stem cells and 
progenitors in other tissues such as hair follicles [27], intestine [28] and mammary 
gland [29]. 
Msi-1 acts by binding the sequences present in the 3’-untranslated region (3’-
UTR) of target mRNA thereby, repressing their function at the translational level 
[30]. Msi-1 represses the translation of mNumb [31], a negative regulator of Notch 
pathway, p21
Cip1
, an inhibitor of cycling-dependent kinase [32], and doublecortin 
(Dcx) a microtubule-binding protein involved in neural stem cell migration [33]. 
These latter mRNA targets are both implicated in cell proliferation and protein 
modification. It has been demonstrated that p21
Cip1
 is absent in Msi-1-expressing 
cells, which is in agreement with the ability of Msi-1 to block its translation. p21
Cip1
 
is believed to function as a rheostat to maintain a balance between stem cell 
quiescence and stem cell exhaustion resulting from increased cell cycle entry. 
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2. CANCER STEM CELLS 
2.1 Identification and origin 
Within tumor masses it has been recently identified a small cell population called 
"tumor initiating cells". These cells present the ability to re-grow the tumor from 
which they were isolated. Several studies have revealed that these cells have the 
capacity of self-renewal, the potential to develop into any cell in the overall tumor 
population and the proliferative ability to drive continued expansion of the 
population of malignant cells. Since the properties of such tumor initiating cells 
mirror those of normal stem cells, in the 1990 was introduce the term Cancer Stem 
Cells (CSC) to better identified such malignant cell population.     
The origin of CSC is still a matter of debate. It is possible that CSC arise from 
mutations that occur in a normal stem cell. However, several lines of evidence 
indicate that CSC could also originate from mutated TA cells. These cells posses 
substantial replicative ability, but they do not usually have the self-renewal capacity 
of stem cells (Figure 4). To become CSC, a TA progenitor cell must acquire 
mutations that confer the property of self-renewal [34]. In any case, a general 
consensus exists that CSC are essential for tumor initiation, progression and 
maintenance.  
Different approaches have led to the identification of CSC: (I) examination of the 
expression of tissue-specific surface markers such as CD44, CD133, CD24 which are 
selectively expressed on CSC but not on the bulk of tumor cells; (II) examination of 
specific functional features of CSC and (III) evaluation of their tumorigenic potential 
when injected into immunocompromised mice at low number. In reference to this 
point, the most common approach to isolate CSC from total tumor population is 
FACS sorting, based on the expression of specific surface antigens recognized as 
stemness markers. Once isolated, CSC are injected in scalar number into 
immunodeficient mice and their tumorigenic potential is compared with the ability to 
form tumors by the same number of non SC.  
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Figure 4. Cancer Stem Cells origin. Mutations can occur in normal SC inducing a 
neoplastic transformation, but can also occur in progenitor cells that acquire stemness 
properties such as indefinite proliferative potential and self-renewal. 
 
 
2.2 Characterization 
In some studies CSC have been recognized by dual-wavelength flow cytometry 
as the so-called Side Population (SP) on the basis of their ability to extrude the 
fluorescent DNA-binding dye Hoechst 33342 [35]. A SP has been identified in both 
several tumors and established cancer cell lines. In breast cancer cell lines, the SP 
population is characterized by a number of features, including an 
ALDH
+
/CD44
+
/CD24
-
 phenotype, spheroid formation ability, clonogenicity, 
multilineage differentiation potential and tumor initiating capacity upon injection 
into NOD/SCID mice [36]. Similar properties were attributed to SP cells isolated 
from DAOY and PFSK medulloblastoma cell lines that contained a small population 
(1.9%) of CD133
+
/Nestin
+
 cells able to form spheroids in vitro and to generate 
xenograft tumors [37]. 
A further approach to identify CSC is based on their replicative potential: under 
standard culture conditions CSC are poorly or non-proliferating cells compared to the 
bulk of tumor cells. By measuring fluorescence intensity following labeling with 
membrane-binding dyes such as PKH26, it is possible to identify cells that proliferate 
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and eventually loose the dye from cells that remain in quiescent state hence maintain 
high intensity of the dye. This technique was recently utilized by the Pelicci’s group 
[38] to identify breast cancer stem cells, recognized as PKH26
high
 cells.  
A large fraction of CSC is likely in a quiescent state and do not respond to 
conventional chemotherapeutics that kill proliferating cells (Figure 5); CSC could 
thus represent the reservoir of drug-resistant cells responsible for relapse after a 
chemotherapy-induced remission. It has been shown that the CD133
-
 fraction of 
human colorectal cancer cells showed a dose-dependent sensitivity to oxaliplatin 
and/or 5-Fluorouracil (5-FU), whereas the CD133
+
 fraction, sorted from the same 
samples, did not undergo drug-induced apoptosis, even by increasing drug 
concentrations [39]. These behavior could be attributed to the fact that CSC exhibit a 
high expression of ATP-binding cassette (ABC) transporters, especially BCRP 
(breast cancer resistance protein or ABCG-2) and MDR1 (multi-drug resistance-1, 
ABCB1 or P-glycoprotein) as part of their self-protection capabilities [40]. ABC 
transporters can power the translocation of substrates across biological membranes 
against a concentration gradient through hydrolysis of ATP and are currently be 
associated with drug resistance. However, ABC transporters are not the sole cause of 
drug resistance in CSC; several other factors, such as the CSC capacity of DNA 
repair and their quiescent state, may also have a key impact on drug resistance [41].  
 
 
 
Figure 5. Traditional versus new cancer therapies. Conventional therapy such as 
chemotherapy kills tumor cells but not CSC that can drive tumor relapse. An hypothetical 
CSC therapy should address to specific features of CSC, thus once eliminate the stem 
counterpart, tumor loses ability to generate new cells and degenerate. 
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2.3 Colon CSC markers 
As for normal SC, CSC are fundamentally isolated thanks to the expression of 
specific markers. The first marker identified for colon CSC was CD133,
 
a pentaspan 
transmembrane glycoprotein also known in humans as Promin-1. Ricci-Vitiani and 
colleagues [42] and O’Brien and colleagues [43] reported that the CD133+ cell subset 
in colorectal carcinoma (CRC) could induce xenograft tumors when injected into 
NOD/SCID mice, a property strictly related to stemness. However, it was 
subsequently reported that CD133 expression is not specific to colon CSC: both CSC 
and progenitors expressed this marker, and both CD133
+
 and CD133
-
 metastatic 
colon cancer cells were able to initiate tumors [44]. Some years later, Dalerba et al. 
suggested that CD44 and EpCAM could represent more robust markers than CD133, 
as CD44 expression could also be detected in tumor cell populations that score 
negative for CD133 expression [45]. Analysis of the surface molecule repertoire of 
EpCAM
high
/CD44
+
 cells led to the identification of CD166 as an additional 
differentially expressed marker, useful for CSC isolation in three of three CRC tested 
[45]. It has also been demonstrated that some markers identified in normal colon SC 
are highly expressed in neoplastic tissues and could be considered as possible CSC 
markers (i.e. Msi-1 [46], Lgr5 [47] and ALDH1 [48]). 
It has been recently demonstrated that none of the putative markers (CD44, 
CD133, CD166 and EpCAM) could define CSC, since CSC isolated according to 
their expression did not exhibit increased survival when treated in vitro with 
chemotherapeutic drugs, nor did they display higher tumorigenicity in vivo [49]. 
 
Marker Other name Function References 
CD133 Prominin 1 Tumor angiogenesis 42, 43 
CD44 CDW44 Cell adhesion molecule, 
Hyaluronic acid receptor 
45 
EpCAM ESA Cell Adhesion molecule 45 
Msi-1  RNA binding protein 46 
Lgr5 GPR49 Unknown, Wnt target gene 47 
ALDH1 ALDC Enzyme 48 
CD166 ALCAM Cell Adhesion molecule 45 
    
 
Table 2. Colon CSC markers. List of  CSC markers identified in human tumoral colon 
tissue. 
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3. COLORECTAL CANCER 
3.1 Neoplastic Progression 
CRC accounts for approximately 150.000 new cases and 56.000 deaths per year 
in the United States, making it the third most common cause of death among men 
and woman [50]. 
It has been suggested that CRC could follow multistep model of neoplastic 
transformation since the transformation of normal mucosal epithelia to invasive 
colorectal carcinoma occurs via a well-coordinated accumulation of mutations in a 
series of critical genes [51]. The first event that occurs during the neoplastic 
progression is the acquisition of a mutation in the adenomatous polyposis coli (APC) 
gene. APC is a tumor suppressor gene that controls the Wnt/β-catenin signaling 
pathway, and its loss translates into accumulation of nuclear β-catenin, leading to the 
constitutive activation of Wnt cascade. Wnt activation is associated with aberrant 
crypt cell proliferation; these cells are unable to exit the crypt and start to expand 
sideways forming hyperplastic or dysplastic tissue. The transition from a dysplastic 
crypt to the so called "intermediate adenoma" necessitates an additional mutation that 
in 50% of the cases involves the Kras gene. KRAS is a small GTP-binding protein 
that transduces signals from surface receptors to the nucleus (Fig 6). As adenomas 
continue to grow and begin to show great histological disorder, there is the gradual 
accumulation of additional mutations in oncogenic genes such as Smad4, Smad 2 and 
DCC. By the end, loss of functional P53 by damage to both alleles drives progression 
to carcinomas. P53 is a fundamental oncosuppressor gene, able to suppress cell 
division and to induce apoptosis in response to stress or damage; its malfunction 
seems to be related to tumor invasiveness and metastatic ability [52]. 
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Figure 6. Model of intestinal cancer initiation and progression.  
Progression from normal epithelium to colorectal carcinoma occurs through adenoma 
formation. Mutations in APC are the first event that mediates the transition of single pre-
neoplastic cells to aberrant crypt foci that develop into adenoma and colorectal carcinoma 
due to mutations in other oncogenes and tumor suppressor genes such as Smad, p53, K-ras 
[53]. 
 
 
2.2 CSC model for neoplastic origin 
 According to the literature there are currently two models that explain the 
cellular origin of cancer:  
1) The hierarchical model (o CSC model) 
2) The stochastic model. 
The CSC model suggests that tumors grow like normal tissues of the body, with SC 
at the starting point of a hierarchical system that produces new cells to make tissue 
grow. According to this idea, tumors contain CSC that divide and feed tumor growth. 
These cells can self-renew extensively and produce mature TA cells which divide 
and differentiate into specialized tumor cells. These specialized tumor cells are no 
longer able to divide, and so they do not contribute to tumor growth. According to 
this idea, the cells in a tumor are organized in a strictly hierarchical fashion, with 
CSC at the top of the tree, giving rise to all other cancer cells. 
In the stochastic model, instead, all cancer cells have the same potential to grow 
and divide, but each cell chooses at random between self-renewal and differentiation. 
The cells in tumor are not arranged in an organized system, and any cell could have 
the same intrinsic potential to contribute to tumor growth. Different types of cancer 
may work in different ways, so it is possible that both of these theories are right.  
The CSC model could be more relevant in the explanation of colon cancer origin. 
In fact, CSC are long-lived cells in the colonic crypt, and thus could accumulate 
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cancer-causing mutations over years or decades. Histological evidence from colon 
tumors indicates that they have multiple differentiated cell types, suggesting a SC 
origin for colon tumors, because only multipotent SC could give rise to so many 
different types of cells within the tumor.  
 
 
Figure 7. Models for cellular origin of Cancer. The cancer stem cell theory suggests a clear 
hierarchical cell organization within a tumor, with SC at the top. The stochastic model, 
instead, describes tumor growth as a random process due to contribute of all different cell 
types. 
 
 
3.3 Metastatic process 
The metastatic process is due to some cancer cells that, according to a complex 
sequence of biological events leave the primary tumor site, enter the lymphatic or 
circulatory system, survive within the circulation flow, overcome host defenses, 
extravasate and then grow as a metastatic tumor [54]. 
Cancer cells, probably CSC, undergo a process named EMT (Epithelial to 
Mesenchymal Transition) through which they acquire migration ability, invasiveness 
and mesenchymal morphology. These features permit EMT cells to dissolve adherent 
and tight junctions, loose cell polarity and invade stromal compartment thanks to the 
action of matrix metallopreoteinase (MMP) that drive the degradation of ECM 
releasing growth factors that stimulate cell proliferation [55]. 
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Once in the stroma, cancer cell aggressive behavior is enhanced by various types 
of signals such as secretion of cytokines or stimuli from tumor-associated 
macrophages (TAM) that drive cell entry into the lumina of lymphatic or blood 
vessels. Intravasation can be facilitated by molecular changes that promote the ability 
of cancer cells to cross the pericyte and endothelial cell barriers that form the walls 
of microvessels. Within the lumina, cancer cells disseminate through the venous and 
arterial circulation as Circulating tumor cells (CTC), surviving to a variety of stresses 
to reach distant organ sites; CTC interact with leukocytes and aggregate with 
platelets, which protect cancer cells against mechanical stress and leukocytes. At this 
point CTC extravasate in specific tissues where microvessel permeability is low due 
to factors released from primary tumor that induce vascular hyperpermeability, thus 
creating a "premetastatic niche" (Figure 8). 
Depending on the site of primary tumor, CTC form metastases in specific organs; 
to date this is a major unresolved issue. It has not known as yet whether CTC tropism 
is due to specific ligand-receptor interactions, between CTC and luminal walls of the 
microvasculature, or to cytokines released from specific organs where CTC 
metastasize. It is also possible that their localization is simply due to CTC arrest in 
the circulatory flow imposed by blood vessels diameter or capillary size and 
restrictions. 
When arrived in anew location, CTC cells switch from mesenchymal to epithelial 
morphology (from EMT to MET [56]). Here metastatic cancer cells can remain in an 
apparent long-term dormancy (defined as "tumor dormancy") until they start to 
proliferate again, eventually inducing new vessel formation for metastatic mass 
feeding. 
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Figure 8. Metastatic process. (A) From primary tumor mass, few cells detach, invade 
stroma and (B) intravasate into the lumina of blood or lymphatic vessels. (C) Once in the 
venous and arterial circulation these cancer cells are called CTC; when arrived in target 
organs CTC arrest and extravasate inducing (D) metastatic growth and formation of a 
secondary tumor in the new appropriate environment. 
 
 
4. THE NOTCH PATHWAY 
4.1 Pathway description 
The Notch gene was first recognized in a mutant Drosophila with an indentation 
in the wings. In the 1930s, it was suggested that the genetic locus responsible for this 
phenotype played an important role in the cell fate decision during Drosophila 
embryogenesis and that the homozygous mutation of this locus resulted in excessive 
differentiation to neuronal tissue.  
Only in the 1980s molecular cloning studies revealed that the Notch gene 
encodes a transmembrane protein that functions as a receptor for the ligand present 
on the cell surfaces of neighboring cells [57]. In mammals, Notch signals through 
four different receptors (Notch1-4) and 5 different ligands. A prototypical Notch 
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gene encodes a single transmembrane receptor composed by an extracellular, a 
juxtamembrane, a transmembrane and a cytoplasmic region. The extracellular region 
presents a conserved array of up to 36 epidermal growth factor (EGF)-like repeats, 
involved in ligand interaction, followed by a cysteine-rich Notch or LIN12 (LN) 
domain. The juxtamembrane region is characterized by specific proteinase cleavage 
sites; the transmembrane region includes a cleavage site while the cytoplasmic region 
contains several functional domains. Furthermore, the cytoplasmic region is 
composed by a RAM (RBP-Jκ- associated molecule) domain, a set of six ankyrin 
(ANK) repeats flanked by two nuclear localization sequences (NLSs), and by a 
transactivation (TAD) domain, which is present only in Notch1 and Notch2 but not 
in Notch3 or Notch4 receptor. Finally, the last domain (PEST) is composed by a tail 
rich in proline, glutamate, serine and threonine [58]. 
The five transmembrane ligands that interact with Notch receptors, Delta-like 
ligand 1 (DLL1), DLL3, DLL4, Jagged 1 (JAG1) and Jagged 2 (JAG2), share 
structural homology, including a DSL domain (Delta, Serrate and LAG2), followed 
by a number of EGF-like repeats (six in the case of DLL3, eight in the case of DLL1 
and DLL4, and 18 in the case of JAG1 and JAG2) [59], with a cysteine-rich (CR) 
domain found only in JAG1 and JAG2, followed by a transmembrane domain and a 
short cytoplasmic tail [60]. 
As shown in Figure 9, the Delta/Jagged–Notch pathway uses a distinct molecular 
mechanism to transduce a signal from the cell surface to the nucleus, and thus to 
regulate expression of target genes. After binding to a Delta ligand, the Notch 
receptor undergoes a series of proteolytic events near the cell surface, including the 
S2 cleavage mediated by A-Disintegrin And Metalloproteinase 10 (ADAM10) or 
TNF-α-converting-enzyme (TACE; also known as ADAM17), followed by the S3 
cleavage mediated by the γ-secretase enzyme complex, resulting in the release of the 
Notch intracellular domain (NICD) which then translocates to the cell nucleus [61]. 
Once in the nucleus, NICD binds to CSL1 and converts it from a transcriptional 
repressor to an activator. Active CSL1 interacts with one of three transcriptional 
regulators MAML-1, and p300⁄CBP, helping to convert the transcriptional co-
repressor (Co-R) complex into an activator complex, and thus induces the expression 
of a panel of target genes [62].  
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The NICD–RBP-Jk complex up-regulates expression of primary target genes of 
Notch signaling that belong to the bHLH family. These proteins are characterized by 
the presence of an Helix-Loop-Helix motif (HLH) and by a DNA-binding basic 
domain. In mammals there are two distinct Notch target families:  
1) Hes (Hairy/Enhancer of Split)  
2) HRT (Hairy-Related Transcription factor), also known as Hey.  
Both Hes and Hey are transcriptional repressors and appear to act as Notch effectors 
by negatively regulating expression of downstream target genes [63].  
In addition, Notch signaling is positively regulated by Musashi-1 that acts 
binding Numb, an inhibitor of NICD nuclear translocation, eventually causing its 
deregulation [64]. 
 
 
 
Figure 9. The Notch Pathway. Following cell-to-cell contact, Delta or Jagged ligands bind 
Notch receptor thus inducing its proteolytic cleavage. NICD is released into the cytoplasm 
and translocates to the nucleus where it acts as a transcriptional activator of Notch-associated 
target genes, including members of HES and HEY family, Pt and p21. NICD nuclear 
translocation is allowed by Msi-1 binding of Numb mRNA and the consequent inhibition of 
Numb function. 
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4.2 Notch Pathway in normal colon mucosa and SC 
In colonic tissue, the Notch pathway plays a central function in the intestinal cell 
fate decisions (Figure 10), in fact it is essential to maintain the crypt compartment in 
its undifferentiated and proliferative state. In the colon, abundant expression of 
Notch1, Jagged1 and Hes1 was observed in the proliferative zone located within the 
middle-third of the crypt. On the contrary, low levels of Notch1 and Hes1 were 
detected at crypt apex, where differentiated epithelial populations are present [65].  
Notch involvement in the intestinal epithelial differentiation was investigated by 
inhibition of the pathway. Conditional deletion of the CSL gene or pharmacological 
inhibition of γ-secretase resulted in the rapid and complete conversion of all 
epithelial cells into goblet cells [66]. On the contrary, gain of function through 
specific over-expression of a constitutively active Notch1 receptor resulted in 
depletion of goblet cells and reduction in enteroendocrine cell differentiation [67].  
Furthermore Riccio et al. showed that conditional inactivation of both Notch1 
and Notch2 receptors in the gut resulted in the complete conversion of the 
proliferative crypt cells into post-mitotic goblet cells [68]. The same effect could be 
observed in intestinal tumors arising in Apc
min
 mice following inhibition of the 
Notch pathway [66].  
 
 
Figure 10. The Notch signaling pathway in colonic crypt. Notch activation is mainly 
restricted in the proliferative zone located in the lower region of the crypt. Moving along the 
crypt wall toward the apex, the levels of Notch and his target gene Hes-1 reduce. 
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As far as the genes controlled by Notch during colon differentiation are 
concerned, it has been demonstrated that differentiation into goblet cells is regulated 
by Atoh1- kruppel-like factor 4 (Klf4) pathway, which translates into activation of 
expression of the gastrointestinal mucin (Muc2). Indeed, Notch target gene Hes1 
represses transcription of the bHLH transcription factor Atoh1, which is directly 
regulated by the Wnt pathway. Hes1
−/−
 animals are embryonic lethal, but the 
intestines from these animals show an increase in goblet, and enteroendocrine cells, 
as well as a decrease in absorptive enterocytes [69, 70]. Likewise, differentiation into 
enteroendocrine cells is guided by Neurogenin3 (Ngn3) that is located downstream 
of the Notch-Hes1-Atoh1 cascade; mice homozygous for a null mutation in Ngn3 
transcription factor do not develop any intestinal endocrine cells [71].  
Finally, enterocyte differentiation is driven by E47-like factor 3 (Elf3), which is 
a target of Hes1 and a member of the Ets transcription family. Indeed, mice 
homozygous for an Elf3 null mutation die shortly after birth and display poorly 
polarized enterocytes that have not reached maturity [72].  
Thus, all these evidences show that the Notch pathway controls absorptive versus 
secretory fate decisions in the intestinal epithelium [73] as well as proliferation of 
undifferentiated compartment versus cells differentiation. 
4.3 Notch in CSC: Therapeutic Implication 
Aberrant Notch activation has been demonstrated in CSC from several tumors, 
including glioma [74] , breast [75], colon [76] and pancreatic cancer [77]. Pancreatic 
CSC, identified by the expression of CD44, CD133, CD24, CD34 and ALDH, 
showed higher levels of Notch-1 and Notch-2 mRNA associated to the loss of 
microRNA-34 (miR-34), compared to pancreatic non-CSC [77]. Since Notch-1 and 2 
are downstream targets of miR-34, these results suggest that miR-34 could be 
involved in pancreatic CSC self-renewal via modulation of Notch activity. Further 
data support a role of other miRs in the regulation of Notch levels in pancreatic CSC. 
Li et al. observed low miR-200 levels in gemcitabine-resistant pancreatic cancer 
cells showing canonical features of CSC; moreover, its forced expression 
significantly inhibited Notch signals [77]. Thus, modulation of specific miRs could 
be a successful strategy to target certain CSC features, such as drug resistance. 
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In colon cancer cells with CSC properties, inhibition of Notch-1 induced a 
reduction in cell proliferation, a cell cycle arrest in G0-G1, and it increased the 
number of apoptotic cells. Moreover, Notch inhibition reduced both spheroid 
formation in vitro and tumorigenic capacity in mice, two established CSC features. 
In contrast, Notch-1 overexpression increased cell proliferation, cell cycle 
progression and it reduced apoptotic cells [78]. 
Another approach to inhibit Notch signalling is to use a -secretase inhibitor 
(GSI), such as GSI-18, to enhance the efficacy of temozolomide monotherapy as 
demonstrated in CD133
+
 glioma CSC [79]. In culture GSI reduced the CSC 
population also in some medulloblastoma cell lines [80] : in fact a 3-fold reduction of 
the CD133
+
 stem-like fraction was cobserved in DAOY cells treated with GSI as 
well as in other medulloblastoma cell lines (D283Med, D425Med and PSFK). On the 
contrary, forced expression of Notch2 intracellular domain (NICD2) in DAOY cells 
increased the CD133
+
 fraction to > 17%. Similar results were obtained by analyzing 
the SP in these cell lines: constitutive activation of Notch2 led to a 4-fold increase of 
SP cells, whereas Notch inhibition almost completely ablated SP. In the same study, 
the CSC fraction expressing the neural stem cells marker Nestin was also analyzed; 
NICD2 activation increased the Nestin
+
 cell fraction from 10% to 47%, whereas 
Notch blockade by GSI reduced this population to about 2.4%. These findings 
buttress the plasticity of the CSC phenotype, a concept which has found experimental 
support in the last two years.  
The main problems associated with GSI is gastrointestinal cytotoxicity; for this 
reason, several “non-toxic natural agents” able to modulate Notch signalling, such as 
curcumin, quercentin, isoflavone, and sulforaphane are being tested.  
More promising approaches are offered by antibodies targeting either Notch 
receptors or Notch ligands. Hoey et al. showed that a neutralizing antibody against 
DLL4 decreased by 50% colon CSC population, defined as ESA
+
/CD44
+
/CD166
+
 
cells. Notably, the combination of anti-DLL4 and Irinotecan further decreased the 
percentage of CSC in treated tumors, whereas Irinotecan monotherapy induced an 
increase from 28% to 43% of the ESA
+
/CD44
+
/CD166
+
 population [81]. Dontu and 
colleagues [82] evaluated the effect of Notch signaling agonists and antagonists on 
breast CSC, cultured either as floating mammospheres or on a collagen matrix, under 
conditions that promote differentiation. A synthetic peptide derived from the Delta-
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Serrate-LAG 2 (DSL) domain conserved in all Notch ligands and a recombinant 
Delta 1 ligand fused to the immunoglobulin Fc fragment were utilized as agonists of 
Notch signaling, whereas a Notch4-specific antibody or a GSI were used as 
antagonists. After treatment with agonists a 10-fold increase in mammosphere 
formation was observed, compared to control cultures; this effect was abrogated by 
anti-Notch 4 antibody or GSI, while these treatments had no effects on differentiated 
mammary epithelial cells.  
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AIM 
 
Aim of this paper is to address the in vitro culture and characterization of distinct 
epithelial cell subsets from normal human colon mucosa. In general, previous 
attempts to grow in long-term culture cells with stem-like properties from normal 
human colon mucosa had been unsuccessful. Very recently, however, Sato et al. [10] 
and Jung et al. [11] succeeded in isolating and expanding in vitro normal human 
colonic stem cells by a positive selection strategy targeting the expression of EphB2. 
In this work, we instead adopted a totally different strategy, and chose to derive cells 
endowed with stem-like properties by simply exploiting their proliferation rate. 
Once described a stem-like cell population in normal colon tissue, we turned to 
tumoral and metastatic colon samples, to identify possible features in such 
population that could be helpful in understanding neoplastic progression and stem 
cell involvement.  
The involvement of the Notch pathway in stem cells maintenance and the 
overexpression of one of its receptor, Notch3, in tumoral and metastatic colon tissue 
has been reported [83]. On the other hand, the activation of Notch intracellular 
domain is due to the action of Msi-1, a colon stemness marker, and to date nothing is 
known about its regulation. Based on these considerations, we tried to describe a 
possible modulation of Msi-1 by Notch3 receptor using a specific metastatic cell line, 
MICOL-14
tum
 cells, and primary human metastatic samples. 
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MATERIAL AND METHODS 
 
1.Primary samples and cell lines  
Following informed consent, 80 histologically normal samples, 5 tumoral colonic 
mucosa samples and 20 liver CRC metastatic samples were obtained from colon 
cancer-bearing patients undergoing colectomy. Immediately after resection, the 
tissues were washed in cold phosphate-buffered saline (PBS) containing 
Penicillin/Streptomycin, gentamicin (1 µl/ml) and amphotericin (1.25 µg/ml). Each 
samples was divided in two parts: one fragment was snap-frozen in liquid nitrogen, 
and stored at -80°C until use, while the other was processed as described elsewhere 
[84]. Briefly, the tissue was minced and incubated for 3 h at 37°C with collagenase 
(1.5 mg/ml) and hyaluronidase (20 µg/ml) in DMEM/F12 medium (Gibco, 
Invitrogen, Carlsbad, CA). The digested material was centrifuged and sequentially 
filtered through 70 and 40 µm filters; red blood cell lysis was performed at 37°C for 
7 min in NH4Cl/ KHCO3/EDTA buffer, and cell viability was assessed by Trypan 
Blue dye exclusion. The cell suspension was then plated in serum-free DMEM/F12 
medium and maintained at 37°C in a 5% CO2 humidified atmosphere in low 
adhesion plate for 1 week. All experiments were performed after a week of reduced 
adhesion condition.  
The MICOL-14
tum
 is a tumorigenic variant of MICOL-14 cells, a cell line derived 
from a lymph node metastasis of rectal cancer [85]. MICOL-14
tum
 has been obtained 
from a tumor developed in NOD/SCID mice after subcutaneus (s.c.) injection of 
parental MICOL-14 cells in Matrigel plus bFGF (100 ng/ml; PeproTech, London) 
and interleukin-8 (100 ng/mL) [86]. Cells were grown in RPMI 1640 medium 
supplemented with 10% FCS and 1% L-glutamine (Invitrogen, Milan, Italy) and used 
within 6 months from thawing and resuscitation. 
 
2. In vitro cell culture and PKH26 staining  
Isolated cells from human colon mucosa specimens were plated at the 
concentration of 2x10
5
 cells/ml in untreated ultra-low adhesion 6-well plates (BD 
Falcon, Franklin Lakes, NJ) and cultured in serum-free DMEM/F12 medium 
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supplemented with Pen/Strep, glucose (6 mg/ml), NaHCO3 (1 mg/ml), HEPES (5 
mM), L-Glutamine (2mM), heparin (4 µg/ml), bovine serum albumin (BSA; 4 
mg/ml), insulin (25 µg/ml), anhydrous sodium selenite (30 nM), progesteron (20 
nM), apo-transferrin (100 µg/ml), epidermal growth factor (EGF; 20 ng/ml, 
PeproTech), basic fibroblast growth factor (bFGF; 10 ng/ml, PeproTech), and 
putrescin (9.6 µg/ml, SigmaAldrich, St. Louis, MO).  
After one week the cells were collected, washed with DMEM/F12 medium and 
incubated for 3 min with a 1:250 (v/v) PKH26 solution (Sigma-Aldrich,) [87]. The 
staining was blocked with 1% BSA and DMEM/F12, and the cells were seeded in 
poly-2-hydroxyethyl methacrylate (PhEMA)-coated plates in the absence of serum at 
2x10
4
 cells/well. According to the proliferation curve, the medium was replaced 
every 7 days. The plates were examined daily by phase-contrast microscopy to 
evaluate the formation of spheroid-like structures, and pictures were acquired with a 
Nikon camera. PKH26-stained cells were also observed with fluorescence 
microscope and pictures acquired with an Olympus camera or confocal microscope 
(Axiovert 1000M, Zeiss, Schwabhausen, Germany).  
 
3. Colony formation assay 
To address the frequency of spheroids-forming cells we performed an extreme 
limiting dilution assay (ELDA) in the presence or absence of -Notch2/3 mAb 
(1l/ml). Briefly, primary colon samples and MICOL-14tum cells were plated at 
different concentrations in 96-well flat-bottom ultra-low attachment PhEMA-coated 
plates (BD Falcon) in a total volume of 0.2 ml of medium described above for 
primary cells and RPMI 1640 serum-free supplemented with EGF and bFGF for 
MICOL-14
tum
cells. At least 30 replicates were set up for each cell concentration. 
According to experimental design, after 4 or 10 days of incubation at 37°C, 5% CO2 
wells were scored for outgrowth of spheroids; the frequency of spheroids-forming 
precursors in each population was calculated using ELDA web tool at 
http://bioinf.wehi.edu.au/software/elda. For normal samples cells were collected at 
the 2
nd
 week of culture and ELDA was performed in both unfractionated and FACS-
sorted PKH
pos
 cells.  
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4. In vitro cell differentiation 
To promote in vitro cell differentiation, cells maintained in serum free conditions 
were FACS-sorted at the 3
rd
 week of culture into PKH
pos
 and PKH
neg
 subsets, and 
included into Matrigel (BD Biosciences) or transferred to untreated 24-well plates, in 
the presence of 10% fetal calf serum (FCS, Invitrogen) and in the absence of bFGF 
and EGF. In both cases, the cells were plated at a density of 5x10
4
 cells/ml. For 
Matrigel cultures, 24-well plates were dispensed with Matrigel-included cells and 
layered with DMEM supplemented with 10% FCS. The cells were maintained at 
37°C in a 5% CO2 humidified atmosphere, and the medium replaced every 2 days. 
 
5. Flow cytometry (FACS) analysis  
According to the experimental design cells were collected weekly or after 72h of 
treatment with -Notch antibodies. Cells were washed in PBS and PKH26 intensity 
(were present) measured by FACS (LSR II, BD Biosciences). The expression of 
CK18 (1:200; Abcam, London UK), CK20 (1:10; Dako, Milan, Italy), Lgr5 (1:400; 
Origene, Rockville, MD), and Msi-1 (1:200; Abcam) was measured by single 
staining or with the appropriate antibody combinations in fixed cells. Cells were 
fixed in 4% Paraformaldehyde and permeabilized with 0.1% Triton X-100. 
Unspecific binding was prevent by saturation with PBS/5% BSA followed by 
incubation with the primary antibody and then with the appropriate secondary 
antibodies (Alexa 1:500, Invitrogen) [88]. Data were collected from at least 5x10
4
 
cells/sample and analyses were performed with Flow Jo (TreeStar, Ashland, OR). 
Cell viability was evaluated by Live/Dead (Invitrogen) staining for 30' at 4°C.  
 
6. Immunohistochemical analysis  
Immunohistochemical staining was performed on formalin-fixed, paraffin-
embedded (FFPE) tissues using a standard avidin-biotin immunoperoxidase complex 
technique (Dako). Briefly, four-μm thick sections were mounted on silanized slides, 
dewaxed in xylene, dehydrated in ethanol, boiled in 0.01 M citrate buffer (pH 6.0) 
for 15 min in a microwave at 95 °C, and incubated with 3% hydrogen peroxide for 5 
min. After washing with PBS, sections were incubated in PBS containing 10% BSA 
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for 30 min, followed by incubation for 45 min at room temperature with monoclonal 
(mAb) mouse anti-human cytokeratin 20 (CK20, 1:200; Abcam) or cytokeratin 18 
(CK18, 1:100; Dako). The incubation with rabbit anti-human Msi-1 (1:100; Abcam) 
and mouse anti-human Lgr5 (1:200; Origene), was performed overnight at 4°C. After 
washings, the sections were incubated with biotinylated goat anti-mouse 
immunoglobulin (LSAB kit, Dako) or anti-rabbit immunoglobulin (Vectastain ABC 
kit, Vector Lab, Burlingame, CA) and peroxidase-conjugated avidin (Dako). Lastly, 
0.02% diaminobenzidine and 1% hydrogen peroxide (Dako) in PBS were used as 
substrates in the color development reaction. Sections were then counterstained with 
hematoxylin.  
 
7. Immunocytochemistry  
PKH26-labeled cells obtained by dissociation of the spheroid structures and 
sorted samples (FACS ARIA II, BD Biosciences) were seeded onto poly-D-lysine-
coated glasses at 5x10
4
 cells/spot; MICOL-14
tum
 cells were instead made growth on 
multiwell chamber. Cells were fixed in 4% paraformaldehyde, followed by 
permeabilization with 0.1% Triton X-100 in PBS. Non-specific binding was 
prevented by saturation with PBS/5% BSA for 30 minutes. The cells were then 
incubated with the following anti-human mAb: Msi-1 (1:100; Abcam), Lgr5 (1:200; 
Origene), CK20 (Ks 20.8, 1:10; Dako), CK18 (1:200; Abcam), Mucin-1 (Muc-1, 
1:100; Abcam) and Notch1 activated domain (N1ICD, 1:800, Abcam). For non-
conjugated antibodies, secondary Alexa Fluor 488-conjugated goat anti-rabbit and 
Alexa Fluor 633-conjugated goat anti-mouse or Alexa Fluor 546-conjugated goat 
anti-mouse antibodies (1:500; Molecular Probes, Invitrogen) were added for 30 
minutes. Glasses were finally washed twice with PBS and mounted in glycerol. 
Where possible nuclei were stained with Topro3 (1:1000, Molecular Probes, 
Invitrogen). Confocal laser scanning microscopy was carried out with a Zeiss LSM 
510 microscope (Zeiss, Jena, Germany) using Argon (488nm) and Helium-Neon 
(543-633nm) laser sources. 
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8. Immunofluorescence analysis on frozen sections 
Immunofluorescence was performed on frozen human colon mucosa samples. 
Briefly, 7-μm thick sections were collected on Superfrost Plus microscope slides 
(Thermo Scientific, Munich, Germany) and dried at room temperature for 20 min. 
Sections were fixed in 4% paraformaldehyde and permeabilized with 0.1% Triton X-
100. Non-specific binding was prevented by incubation in PBS/5% BSA for 1 h. 
Staining was carried out by incubating the sections with the anti-Msi-1 (1:100; 
Abcam) and anti-CK20 (9:50; Dako) antibodies for 30 minutes at room temperature. 
After three washes in PBS, appropriate secondary Alexa-conjugated antibodies 
(1:500; Molecular Probes, Invitrogen) were added for 1h. Nuclear staining was 
performed by propidium iodide (PI) incubation (1:10.000; Invitrogen) and pictures 
acquired with confocal Zeiss LSM 510 microscope at 20x and 40x magnification. 
 
9. RNA extraction, reverse transcription and quantitative Real-Time PCR 
(qRT-PCR) assay  
Total RNA was extracted from different cell populations, spheroids, in vitro 
differentiated cells, and microdissected samples by the TRIzol method, according to 
the manufacturer’s instructions. cDNA was synthesized from 0.5-1 μg of total RNA 
using the Superscript II reverse transcriptase (Invitrogen). Fifty-five ng of cDNA 
were used as a template and mixed with 10 μl of 2X Platinum SYBR Green qPCR 
SuperMix-UDG (Invitrogen) and primers, listed in Table 3, in a reaction volume of 
20 μl. Cycling conditions were 10 min at 95°C, 60 cycles of 15 s at 95°C and 1 min 
at 60°C. Each sample was run in duplicate on ABI PRISM
®
 7900HT Sequence 
Detection System (PE Biosystems, Foster City, CA). Results were analyzed using the 
comparative ΔΔCt method: data are presented as the fold difference in gene 
expression, normalized to the housekeeping gene β2-microglobulin and relative to a 
relevant reference sample. qRT-PCR efficiency was always in the range 95-105%. 
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Table 3 Sequences of the primers used in qRT-PCR experiments. 
 
 
10. Notch assay 
To stimulate Notch signaling, P12 wells were coated with soluble recombinant 
human DLL4 (4 μg/ml) (R&D, Minneapolis, MN, USA) in PBS/BSA 0.1%. One day 
later, MICOL-14
tum
 or primary sample cells were added at a concentration of 2x10
5
 
cells/well in RPMI-1640 medium supplemented with 10% FCS and 1% L-glutamine 
(Invitrogen) and cultivated for 72 h prior to subsequent analysis. The monoclonal 
antibodies, including -Notch2/3 (OMP-59R5) and the control antibody (CTRL) 
(OMP-1B711), kindly provided by OncoMed Pharmaceuticals Inc, (Redwood City, 
CA) were used at 10 μg/ml final concentration. 
 
11. Western Blotting 
According to experimental design after 72 h of treatment, or after 3 weeks of 
culture, FACS-sorted PKH
pos
 cells, in vitro differentiated cells or cells treated with 
-Notch2/3 antibody were harvested, lysed and subjected to SDS-polyacrylamide 
gel electrophoresis and Western Blotting (WB). The membrane was saturated with 
Gene 
name 
Forward Reverse 
Lgr5 5’-CTCTTCCTCAAACCGTCTGC-3’ 5’-GATCGGAGGCTAAGCAACTG-3’ 
Msi-1 5’-GGTTTCCAAGCCACAACCTA-3’ 5’-TCGGGGAACTGGTAGGTGTA-3’ 
CK20 5’-GACGCCAGAACAACGAATACC-3’ 5’-ACGACCTTGCCATCCACTAC-3’ 
2Micro 5’-TCTCTCTTTCTGGCCTGGAG-3’ 5’- TCTCTGCTGGATGACGTGAG-3’ 
Bmi-1 5’-GCATCGAACAACGAGAATCA-3’ 5’-TACCCTCGACAAAGCACACA-3’ 
EpCAM 5’-CCAGAACAATGATGGGCTTT-3’ 5’-GCACTGCTTGGCCTTAAAGA-3’ 
ALDH1 5’-CCCGTTGGTTATGCTCATTT-3’ 5’-TGCTCTGCTGGTTTGACAAC-3’ 
Muc-1 5'-AGTTCAGGCCAGGATCTGTG-3' 5'-GAAATGGCACATCACTCACG-3' 
Muc-2 5-'ACCCGCACTATGTCACCTTC-3' 5'-GGGATCGCAGTGGTAGTTGT-3' 
EpHB2 5’-TCCATCTGGGACTTTCAAGG-3’ 5’-TGTTGATGGGACAGTGGGTA-3’ 
Notch-1 5'-GTGCCCTCATGGACGACAAC-3' 5'-GCATCCAGGTGCTGCTGAGT-3' 
Notch-2 5'-CAGCCTGTATGTGCCCTGTG-3' 5'-GTGCTCCCTTAAAACGTGCA-3' 
Notch-3 5'-CAAGGGTGAGAGCCTGATGG-3' 5'-GAGTCCACTGACGGCAATCC-3' 
Hes-1 5'-CAGCGGGCGCAGATGAC-3' 5'-CGTTCATGCACTCGCTGAAG-3' 
Hey-2 5'-GGCGTCGGGATCGGATAAAT-3' 5'-GCGTGTGCGTCAAAGTAGCC-3' 
Numb 5'-AGCCAGCCCATACTGCTCTA-3' 5'-CGGACGCTCTTAGACACCTC-3' 
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PBS/5% non-fat dry milk (Sigma Aldrich) for 1 h at room temperature. 
Immunoreactivity was evaluated by hybridization using the following antibodies: 
rabbit anti-Msi-1 (1:1000; Abcam), mouse anti-Muc-1 (1:1000; Abcam), rabbit anti-
Numb (1:500; Millipore, Billerica, MA, USA), rabbit anti Notch1 activated domain 
(N1ICD, 1:1000; Cell Signaling, Beverly, Massachusetts) and mouse anti- α tubulin 
(1:5000; Sigma Aldrich). The blots were then hybridized with a 1:5000 dilution of 
HRP-conjugated anti-mouse or anti-rabbit antibody (Amersham-Pharmacia, Little 
Chalfont, UK). Finally, the signal was detected by chemiluminescence with 
SuperSignal kit (Pierce, Rockford, IL). 
 
12. Reporter gene assay 
MICOL-14
tum
 cells were transiently co-transfected using lipofectamine 2000 
(Invitrogen) with a CSL-luc plasmid, a Notch-responsive reporter construct carrying 
the luciferase reporter gene under the control of a promoter containing CSL binding 
sites [89], and a plasmid encoding -galactosidase under the control of the human 
CMV promoter, which was used to normalize transfection efficiency. One day later, 
cells were split and cultivated for additional 48 h on wells coated with human DLL4 
(4 g/ml) or BSA, as control. Each experiment was repeated at least three times. 
Cell lysates were harvested 72 h post-transfection and luciferase and -
galactosidase assays were carried out using BriteLite Plus (Perkin-Elmer, Waltham, 
Massachusetts) and Tropix
®
 Galacto-Light™ (Applied Biosystems), respectively, 
on a plate luminometer (Perkin-Elmer).  
 
13. Transduction of cells with viral vectors  
Lentiviral vectors encoding shRNA targeting human Notch3 or a scrambled 
shRNA as control were purchased from Sigma-Aldrich and used as previously 
reported [83]. The CEG-N3 retroviral vectors, encoding constitutively active forms 
of human Notch3 and the control CEG vector have been described in detail 
elsewhere [90]. The Notch2 ICD encoding retroviral vector (pMSVpuroICN2) was 
a gift from Adolfo Ferrando (Columbia University, NY). The human DLL4-EGFP 
and the control retroviral construct lacking DLL4 have been previously described 
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[91]. Vector stocks were generated by a transient three-plasmid vector packaging 
system, as previously described [92]. For transduction of MICOL-14
tum
 cells, 200 
μL of concentrated vector-containing supernatant were layered over target cells that 
had been seeded into 12-well culture plates at 1 × 10
5
 cell/well. After 6 to 9 h at 
37°C, the supernatant was replaced with 2 mL of complete medium. Assessment of 
transgene expression was performed 72-96 h after transduction. 
 
14. Cells Isolation by Laser Microdissection 
Snap-frozen colon biopsies were embedded in cryostat embedding medium (Bio 
Optica, Milan, Italy), cut into serial 7-μm sections and collected onto PEN-
membrane slides (Leica, Wetzlar, Germany). Sections were fixed in 70% ethanol 
followed by nuclear staining with hematoxylin and dehydration in alcohol. Only 
longitudinally cut crypts were considered for microdissection. Three cell populations 
were isolated: putative stem-like cells at the very crypt base (2-3 cells/crypt), 
Transient-Amplifying (TA) cells located along the crypt wall, and terminally 
differentiated cells at the crypt apex and mucosal surface. Each population was 
isolated by a laser microdissection system (Leica DM6000 B), and collected on the 
test tube cap. For each population at least 1x10
4
 cells were collected in the 
appropriate amount of TRIzol (Invitrogen), and kept at -80°C until RNA extraction. 
 
15. Tumorigenicity assay  
NOD/SCID mice were purchased from Charles River (Wilmington, MA, USA). 
Procedures involving animals, and their care, were performed according to 
institutional guidelines that comply with national and international laws and policies 
(EEC Council Directive 86/609, OJ L358, 12 December 1987). For tumor 
establishment, MICOL-14
tum
 cells were washed and resuspended in PBS. Seven- to 
nine-week-old male mice were injected subcutaneously with 5x10
5
 cells in a 200 μl 
total volume in both dorsolateral flanks. At the tumors establishment, mice were 
sacrificed by cervical dislocation; tumors were harvested by dissection, fixed in 
formalin and embedded in paraffin (FFPE) for immunohistochemical analysis. 
 41 
16. Statistical Analysis   
Data of replicate experiments were shown as mean value ± Standard Deviation 
(SD). Comparisons between groups were made by the Student’s t-test. 
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RESULTS 
 
1. NORMAL COLON STEM CELLS 
1.1 Identification of a slowly cycling cell population and in vitro spheroid 
formation  
Following isolation from fresh normal colon mucosa samples, the cells were 
stained in vitro with PKH26, a dye which binds membrane phospholipids, thus 
conferring a bright red fluorescence [86]. PKH26 staining may represent an 
unconventional proliferative assay and a surrogate marker of stemness, akin DNA 
labels such as Bromodeoxyuridine (BrdU). In fact, the dye segregates during each 
cell division, and a progressive decrease of fluorescence intensity in daughter cells 
can be observed [93], allowing to monitor by FACS the cells which proliferate more 
slowly based on their brighter appearance. Immediately after staining, >98% of the 
cells were PKH
pos
 (Fig. 11A); in the subsequent weeks, a progressive increase in the 
number of cells expressing the dye at low intensity (PKH
low
) was observed, until 
virtually only cells with high PKH26 expression (PKH
high
) remained (Fig. 11A), 
indicating that the cultures contained cells with different replicative potential.  
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Figure 11. Kinetics of PKH26 and in vitro spheroid formation.  
(A) Cells obtained from human normal colon samples were cultured in vitro as detailed in 
Materials and Methods, and stained with PKH26. Cytofluorimetric analysis of PKH staining 
over 6 weeks of culture showed the progressive selection of a cell population expressing the 
dye at high intensity. At the 3
rd
 week of culture, within the PKH
pos
 subset it was possible to 
distinguish two major peaks (PKH
high
 and PKH
low
). One representative experiment is shown. 
(B) Three weeks after PKH26 staining, PKH
pos 
and PKH
neg
 cells were FACS-sorted and 
cultured under serum-free conditions as detailed in Materials and Methods. While PKH
neg 
cells rapidly died in culture (left panel), PKH
pos 
cells began to form spheroid-like structures, 
which progressively grew over time in culture (right panels; magnification 20x, scale bars: 
100m). (C) Confocal microscopy analysis of spheroids showed cells with different intensity 
of PKH26 staining at 3 weeks of culture; magnification 20x. (D) Spheroids obtained after 3-
week culture from PKH
pos 
cells isolated from tumor [T] and pre-cancerous [PC] human colon 
samples were morphologically comparable to those obtained from normal [N] colon tissue. 
Scale bars: 100 µm. (E) Kinetics of cell survival in culture; in the absence of serum, the 
number of living cells decreased until about 5% of input cells at the end of the culture 
period. Results obtained in 4 consecutive experiments are shown. (F) CK18 staining of a 
human colon mucosa section (10x magnification). (G) Kinetics of CK18 expression in 
cultured colon cells; data are expressed as mean values  SD of six different experiments. 
 
Several studies have demonstrated that under specific culture conditions one of the 
major properties of cancer stem cells is their ability to form spheroids in vitro [94-
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95]. When PKH
pos
 and PKH
neg
 cells were FACS-sorted at the 3
rd
 week after PKH 
staining, and cultured in the absence of serum as detailed in Materials and Methods, 
within a few days PKH
pos
 cells began to form small, round cell clusters which grew 
into spheroid structures (Fig. 11B), whereas sorted PKH
neg
 cells died within 2-6 
days, and no spheroid-like structures could be observed. Confocal microscopy 
analysis revealed that these spheroids contained a heterogeneous mixture of cells 
with different PKH26 staining intensity and cells negative for the dye, often spatially 
segregated within a same structure (Fig. 11C). By a limiting dilution assay, in three 
consecutive experiments the frequency of spheroid-forming cells was ranged for 
1/100 to 1/220 PKH
pos
 cells, whereas, as expected, this frequency was much lower 
when unfractionated epithelial cells were plated (Table 4).  
 
Table 4. Extreme limiting dilution analysis of spheroid-forming cell precursors in 
normal colon epithelial cell populations. P-value <0.0001; Data were pooled from three 
independent experiments.  
 
 
Microscopic evaluation showed that spheroids obtained from purified PKH
pos
 cells 
from normal colon mucosa were fully comparable to those obtained from PKH
pos
 
cells isolated by the same technique from colon tumors and pre-cancerous lesions 
after 3 weeks of culture (Fig. 11D).           
On the other hand, the surviving PKH
pos
 subset was a minority of the original 
population, as the total number of cells in culture decreased over time, and by 6 
weeks only about 5% of the cells originally present at the beginning of the culture 
Number of 
cells/well 
Number of 
wells plated 
Number of wells showing spheroids 
  Unfractionated cells PKH
+
 cells 
10,000 30 30 30 
2,000 30 18 30 
400 30 9 26 
80 30 2 16 
16 30 0 12 
3 30 0 5 
Spheoids forming frequency  1/1,748 1/107 
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could be recovered (Fig. 11E). Flow cytometry analysis for CK18, a known marker 
of colon epithelium (Fig. 11F), revealed that early in culture the majority of the cells 
also expressed CK18 (Fig. 11G); this percentage increased over time, with >95% of 
the surviving cells positive for both PKH26 and CK18 by 5 weeks of culture (Fig. 
11G). Altogether, the above results pointed to the existence, within epithelial colon 
cells, of a slowly dividing subset able to maintain PKH26 staining in vitro, which 
could be a suitable candidate for a stem cell-containing population.  
 
1.2 Stemness marker expression by in vitro cultured colon cells  
To characterize the cell population responsible for spheroid generation, we 
analyzed the expression of two putative markers of colon stem-like cells, Msi-1 [30] 
and Lgr5 [96, 97]. As judged by immunohistochemistry on colon biopsies, Msi-1 
staining was substantially confined to the crypt basement (Fig. 12A, left panel), 
where colon stem cells are expected to reside [98], while  the paucity of Lgr5-stained 
cells at the very crypt bottom (Fig. 12A, right panel) fully confirmed previous data 
[47]. As demonstrated by three-color cytofluorimetry at the 3
rd
 week of culture, Msi-
1
+
 cells were mainly confined within the slowly cycling PKH
high
 cell population, but 
a sizable fraction of PKH
low
 cells also expressed this marker, whereas no Msi-1 
expression could be detected in PKH
neg
 cells (Fig. 12B, middle panel). Lgr5 
expression, instead, was entirely restricted to PKH
high
 cells, and no Lgr5 expression 
was recorded in epithelial cells showing lower PKH26 levels (Fig. 12B, lower panel).  
Flow cytometry analysis revealed that the percentage of Msi-1
+
 and Lgr5
+
 cells 
increased over the culture period (Fig. 12C); at the 4
th
 week of culture 28.7  2.4% of 
the PKH
high
 cells expressed the Msi-1 antigen, while 24.9  3.6% expressed Lgr5, 
thus indicating an enrichment of Msi-1
+
 and Lgr5
+
 cells in the PKH
high
 population. 
As shown in Figure 12D, at all times of culture Lgr5
+
 cells invariably co-expressed 
Msi-1, and this subset consistently augmented over the culture period, while a small 
population of Msi-1
+
 cells that did not express Lgr5 was found, which underwent 
progressive reduction late in culture (Fig. 12D).  
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Figure 12. Expression of stemness-associated markers in cultured colon cells.  
(A) Immunohistochemical analysis of Msi-1 and Lgr5 expression in human normal colon 
biopsies; Msi-1
+
 and Lgr5
+
 cells are localized at the crypt base, where bona fide stem-like 
cells home; magnification is indicated in the boxes. (B) Cytofluorimetric analysis of Msi-1 
and Lgr5 expression by PKH26-labelled cells expressing different intensities of PKH26 
staining (PKH
neg
, PKH
low
 and PKH
high
; upper panel) at the 3
rd
 week of culture. Msi-1
+
 cells 
were found within both PKH
high
 and PKH
low
 cell populations (middle panels), whereas Lgr5
+
 
cells were confined to the PKH
high
 subset (lower panels). One representative experiment out 
of three consecutive is shown. (C) Cytofluorimetric analysis of Msi-1 and Lgr5 expression 
by PKH
high
 cells over 4 weeks of culture. Data are expressed as percent mean values (± SD) 
of 5 consecutive experiments. (D) Kinetics of Msi-1 and Lgr5 expression by PKH
high
 cells at 
the 2
nd
, 3
rd
 and 4
th
 week of culture. All Lgr5
+
 cells also co-expressed Msi-1, whereas a small 
fraction of Msi-1
+
 cells did not express Lgr5. One representative experiment out of 4 is 
shown. (E) qRT-PCR analysis of expression of Bmi-1, EphB2, EpCAM and ALDH1 in 
FACS-isolated Msi-1
+
/Lgr5
-
 and Msi-1
+
/Lgr5
+
 cell subsets at the 3
rd
 week of culture. Data 
were calculated as mean values  SD as detailed in Materials and Methods, normalized to 
the housekeeping gene β2-microglobulin and relative to the reference sample (Msi-1
+
/Lgr5
-
 
cells). * p<0.05. 
  
 
 
We also compared in FACS-purified Msi-1
+
/Lgr5
-
 and Msi-1
+
/Lgr5
+
 cells the 
expression of other putative markers for colon stem cells, such as Bmi-1 [99], EphB2 
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[100], EpCAM [45], and ALDH1 [101]. qRT-PCR analysis of FACS-sorted cells 
after 3 weeks of culture revealed that the mRNA expression levels of all these genes 
were consistently higher (p<0.05) in Msi-1
+
/Lgr5
+
 than in Msi-1
+
/Lgr5
- 
cells (Fig. 
12E). Thus, these findings seemed to indicate that the Msi-1
+
/Lgr5
+
 cell population is 
strongly enriched in stem-like cells, compared to Msi-1
+
/Lgr5
-
 cells. Altogether, the 
above data seemed also to delineate the existence of a sort of stemness "gradient" in 
the cultured population, where at least 3 discrete cell subsets could be identified, a 
PKH
high
/Lgr5
+
/Msi-1
+
 population (reasonably reflecting relatively quiescent cells 
endowed with most prominent stem-like properties), a PKH
high
/Lgr5
-
/Msi-1
+
 subset 
(likely reflecting cells with a slow division rate, which lost the expression of a key 
stemness marker such as Lgr5), and a PKH
low
/Lgr5
-
/Msi-1
+
 population which had 
likely undergone more cycles of replication. 
 
1.3 Stemness and differentiation marker co-expression by in vitro cultured cells  
CK20 is considered as a marker of differentiated intestinal epithelial cells [47]; a 
preliminary confirmation of the ability of anti-CK20 antibody to identify 
differentiated epithelial cells was obtained by immunohistochemistry in colon 
sections (Fig. 13A). CK20 expression was mostly confined, as expected, to PKH
neg
 
cells (Fig. 13B), which reasonably underwent more cycles of replication. 
Surprisingly, although the vast majority of CK20
+
 cells did not express Msi-1 (Fig. 
13B), double staining with anti-Msi-1 and anti-CK20 antibodies of cells cultured for 
3 weeks revealed the presence of a small population expressing both markers only in 
the PKH
high
 subset (Fig. 13B). In 4 consecutive experiments, Msi-1
+
/CK20
+
 cells 
accounted for 5.13  0.32% of this most brilliant population. No co-expression of 
Lgr5 and CK20 was observed (not shown), and the Msi-1
+
/CK20
+
 population was 
virtually absent in the PKH
low
 subset. The presence of a small population expressing 
both Msi-1 and CK20 was also supported by confocal microscopy analysis of cells 
cultured for 3 weeks (Fig. 13C).  
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Figure 13. Expression of Msi-1 and CK20 in cultured colon cells  
(A) Immunohistochemical analysis of CK20 showed labeling of the epithelial cells along the 
crypt wall and at the mucosal surface, but not at the crypt bottom. (B) Cytofluorimetric 
analysis of Msi-1 and CK20 expression by PKH
neg
, PKH
low
 and PKH
high
 populations at the 
3
rd
 week of culture; a small subset of PKH
high
 cells co-expressed both markers. One 
representative experiment out of 4 consecutive is shown. (C) Confocal microscopy analysis 
of CK20 and Msi-1 expression in PKH
pos
 cells. The cells co-expressing both markers are 
indicated by an arrow. Magnification 40x. (D) Immunofluorescence analysis of Msi-1 and 
CK20 expression in frozen colon sections. Double-positive cells are evident at the very crypt 
base. (E) qRT-PCR analysis of Muc-1 and Muc-2 expression on FACS-sorted Msi-1
+
/CK20
-
 
and Msi-1
+
/CK20
+
 subsets at the 3
rd
 week of culture. Data are calculated as mean values  
SD as detailed in Materials and Methods, normalized to the housekeeping gene β2-
microglobulin and relative to the reference sample (Msi-1
+
/CK20
-
 cells). *p<0.05. 
 
In view of the possible artefactual nature of these findings, we addressed the 
presence of these double-positive cells in colon crypt sections. As shown in Figure 
13 D, the in vivo presence of Msi-1
+
/CK20
+
 cells could be demonstrated by 
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immunofluorescence analysis of frozen colon sections. This observation confirms 
previous data by Dalerba et al. [102], who identified CK20
+
 goblet cells in close 
proximity to the more immature cellular compartment of the crypt bottom. Indeed, 
quantitative PCR analysis of FACS-sorted Msi-1
+
/CK20
+
 and Msi-1
+
/CK20
-
 cells at 
the 3
rd
 week of culture revealed a significantly higher expression of Muc-1/2 in the 
double-positive subset (Fig. 13E). 
 
1.4 Molecular analysis of in vitro cultured cells and microdissected colon crypt 
populations 
The expression of genes putatively reflecting different stemness and 
differentiation stages was also compared by qRT-PCR in PKH
high
, PKH
low
 and 
PKH
neg
 cells sorted after 3 weeks of culture, and in cells isolated from different colon 
crypt portions by microdissection. PKH
high
 cells showed significantly higher 
(p<0.05) mRNA levels of both Msi-1 and Lgr-5, as compared to PKH
low
 cells, while 
no expression of these genes was detected in the PKH
neg 
subset (Fig. 14A). As 
expected, opposite results were obtained for CK20 mRNA levels, which were 
significantly higher in the PKH
neg
 and PKH
low
 cell subset (Fig. 14A). By taking 
advantage of the discrete location of the cells within the colon mucosa, the above 
results were compared to mRNA levels of the same genes in three colon cell 
populations isolated through laser microdissection (Fig. 14B): cells at the very crypt 
bottom (which bona fide include Crypt Basal Columnar, CBC, cells and would 
correspond to cultured PKH
high
 cells), TA cells along the crypt wall (which are 
reasonably representative of cultured PKH
low
 cells) and terminally differentiated cells 
at the crypt apex and mucosal surface (likely reflecting PKH
neg
 cells). As expected, 
Msi-1 and Lgr-5 mRNA levels were much higher in the basal crypt cell population, 
and barely or not detectable at all in terminally differentiated cells (Fig. 14C). Thus, 
these data further buttressed the idea that the in vitro derived PKH
high
 population 
could indeed contain colon cells endowed with stem-like properties. 
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Figure 14. Comparison by qRT-PCR of stemness and differentiation marker expression 
in cultured colon cells and microdissected colon crypt populations. 
 mRNA levels of Lgr5, Msi-1 and CK20 genes were evaluated by qRT-PCR on  FACS-
sorted PKH
high
, PKH
low 
and PKH
neg
 cells at the 3
rd
 week of culture (Panel A) and on 
Differentiated (Diff), TA and CBC cells (Panel C) isolated by laser microdissection from 
colon crypts (as shown by the picture reported in Panel B). Data are shown as mean values  
SD calculated as described in detail in Materials and Methods, normalized to the 
housekeeping gene β2-microglobulin and relative to the reference sample (PKH
low
 for sorted 
cultured cells, and TA for cells isolated by microdissection). * p<0.05. 
 
1.5 In Vitro differentiation of cultured colon cells  
To evaluate the differentiation potential of PKH26-stained cells, PKH
pos
 and 
PKH
neg
 subsets were sorted at the 3
rd
 week of culture, and cultured in the presence of 
10% FCS, in both uncoated and Matrigel-coated tissue culture plates. Under both 
culture conditions, PKH
neg
 cells died within 10 days (not shown), whereas PKH
pos
 
cells survived but did not form spheroids, as they did in the absence of serum (Fig. 
15A, upper panel). On the other hand, under differentiating conditions these cells 
showed a substantial proliferative potential and the ability to grow into organized 
structures; as shown by phase-contrast microscopy, in the presence of serum PKH
pos
 
cells adhered to the plate assuming an epithelial morphology (Fig. 15A, middle 
panel), while in the presence of Matrigel, although not forming organoids similar to 
those recently described by Sato et al. [10], they generated branched structures of 
cells growing around "holes" (Fig. 15A, lower panel). Cytofluorimetric analysis 
revealed that the differentiated cells completely lost Msi-1 and Lgr5 expression just 
after 10 days of culture in serum and adhesion conditions (Fig. 15B). These data 
were also confirmed by WB analysis (Fig. 15C), which showed significantly higher 
 52 
levels of Msi-1 protein in spheroids, compared to differentiated cells; these latter 
showed instead much higher levels of Muc-1 protein than cells grown under non-
differentiating conditions (Fig. 15C). Furthermore, by comparing RNA extracted 
from both PKH
pos
 spheroid-forming cells and differentiated cells, we demonstrated 
an enrichment in the expression of the differentiation markers CK20, Muc-1 and 
Muc-2 (p<0.05) in PKH
pos
 cells maintained in adhesion condition and in the presence 
of serum for 10 days (Fig. 15D). Immunofluorescence analysis showed a partial loss 
of the PKH26 membrane labeling, which assumed a patchy pattern at the cells 
surface (Fig. 15E); furthermore, these cells expressed the differentiation markers 
Muc-1 (sample #1) and CK20 (sample #2), whereas Msi-1 expression was no longer 
detectable (Fig. 15E).   
 
 
 53 
 
 
Figure 15. In vitro differentiation of cultured PKH
pos
 cells.  
(A) After 3 weeks of culture the spheroids obtained from PKH-stained cells maintained in 
serum-free medium in non-adherent plates (upper panel) were dissociated, and PKH
pos
 cells 
were FACS-sorted and cultured in the presence of 10% FCS in adherent plates or included 
into Matrigel. In both conditions, the cells changed their morphology (lower panel), and in 
the presence of Matrigel they formed branched structures surrounding a "hole". (B) 
Cytofluorimetric analysis of Msi-1 and Lgr5 expression in PKH
pos
 cells cultured for 3 weeks 
in serum-free conditions (Spheroids) and after 10 days in differentiating conditions 
(Differentiated). (C) WB analysis of Msi-1 and Muc-1 proteins in Spheroids and 
Differentiated cell lysates. α-tubulin was used as a control for protein contents. (D) qRT-
PCR analysis of CK20, Muc-1 and Muc-2 expression in Spheroids and Differentiated cells. 
Data are calculated as mean values  SD as detailed in Materials and Methods, normalized 
to the housekeeping gene β2-microglobulin and relative to the reference sample (spheroid 
cells). *p<0.05. (E) Confocal microscopy analysis of differentiated cells. In the presence of 
serum and adhesion conditions, the cells presented a fragmented PKH26 dye pattern along 
the cellular membrane, completely loosing the expression of Msi-1 while acquiring Muc-1 
(sample # 1) and CK20 (samples #2) expression.  
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2. METASTATIC COLON CANCER STEM CELLS 
2.1 Identification of a Slowly Cycling Cell Population and In Vitro Spheroid 
Formation  
Once identified in normal samples a hierarchy of cell populations, we tried to 
describe their presence also in primary samples of colorectal cancer (CRC) and liver 
metastases from the same tumor. Thus we collected 5 primary CRC tumors and 15 
metastatic samples, that were processed as described in Material and Methods. The 
cells were isolated, stained with PKH26, and cultured in PhEMA-treated plate in the 
absence of serum. 
Flow cytometry analysis of PKH26 intensity revealed that, as the normal 
counterpart, in tumor samples after staining, more than 98% of the cells were 
PKH
pos
; this percentage decreased during in vitro culture, until at the fourth week of 
culture mostly cells with high PKH26 expression remained (Fig. 16A) accounting for 
70% of the total population. On the contrary, in the metastatic samples the PKH 
analysis did not definitely document an in vitro selection of a slowly cycling 
population (PKH
high
). The percentage of PKH
pos
 cells decreased over the culture 
periods; the PKH
high
 subset progressively disappeared, until mostly PKH
low
 cells 
remained in culture, accounting for 65% of the total cell population at the fifth week 
(Fig. 16B). This event could reflect a continuous proliferation of metastatic cells 
even in the absence of serum, probably due to mutations accumulated during the 
neoplastic progression (Fig. 16C). 
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Figure 16. PKH26 kinetic in tumor and metastatic samples. 
A) Cells obtained from human CRC samples were cultured in vitro as detailed in Materials 
and Methods, and stained with PKH26. Cytofluorimetric analysis of PKH stained cells over 
5 weeks of culture showed the progressive selection of a cell population expressing the dye 
at high intensity, as in normal samples. One representative experiment is shown; B) Cells 
isolated from metastatic samples and stained with PKH26. Contrary to normal and tumor 
samples, cytofluorimetric analysis showed a selection of metastatic cells with an 
intermediate PKH intensity (PKH
low
); one representative experiment is shown; C) Percentage 
of cells expressing the dye (PKH26) at different intensity: high, low and neg. Data, acquired 
by cytofluorimetryc analysis, are expressed as mean SD of six different experiments. 
 
In metastatic samples we evaluated the cell ability to form spheroidal structures: 
PKH
pos
 cells (both PKH
high
 and PKH
low
) were FACS-sorted from total population and 
cultured in PhEMA-treated plates. After 14 days, about 68% of samples were able to 
form spheroids that grew over time (Fig. 17A) independently from chemoterapic 
treatments of the patients (Table 5). Confocal microscopy analysis revealed that 
these spheroids, as well as those formed by normal samples, contained a 
heterogeneous mixture of cells with different PKH26 intensity (Fig. 17B). 
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Figure 17. Spheroid formation in metastatic CRC samples  
A) Sorted PKH
pos
 cells in PhEMA started to form spheroid-like structures that progressively 
grew over time in culture (magnification 20x, scale bar 100 m); B) Confocal microscopy 
analysis of a spheroid obtained from sorted PKH
pos
 cells; cells with different intensity of 
PKH26 are present within the spheroidal structure (magnification 20x). 
 
Sample ID Treatment Spheroids 
HM#1 Folfiri Yes 
HM#2 no ct neoadiuvant Yes 
HM#3 Folfox No 
HM#4 Folfiri+Bevacizumab Yes 
HM#5 no ct neoadiuvant No 
HM#6 5Fu + Oxaliplatino yes 
HM#7 Folfiri + Bevacizumab yes 
HM#8 Folfiri + Bevacizumab yes 
HM#9 no ct neoadiuvant no 
HM#10 Folfox yes 
HM#11 Folfiri yes 
HM#12 Xelox no 
HM#13 no ct neoadiuvant yes 
HM#14 Xelodia yes 
HM#15 no ct neoadiuvant no 
Table 5. Metastatic CRC samples 
The table correlates each sample, and patient chemioterapic treatment, with cell spheroid 
formation capability. 
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2.2 Stemness marker expression in metastatic CRC samples 
We decided to evaluate putative stemness marker expression in the metastatic 
samples. The expression of the two stemness markers Lgr5 and Msi-1 was evaluated 
by flow cytometry after one week in low adhesion condition and during cell 
maintenance in PhEMA-treated plate. As for the normal counterpart, ex vivo, was 
identify a subset co-expressing Lgr5 and Msi-1 (Fig. 18A) accounting for about 9.8 
3.4% of the total population. By three-color cytofluorimetry, it appeared evident 
that double-positive Lgr5/Msi-1 cells were not completely confined within the 
slowly cycling PKH
high
 cell population, but a sizable fraction was also present in 
PKH
low
 cells, while no Lgr5 or Msi-1 expression was recorded in PKH
neg
 cells (Fig. 
18B). Thus, interestingly, at variance with normal samples, Lgr5
 
is expressed not 
only by the slowly cycling PKH
high
 cells but also by the PKH
low 
subset. Marker 
distribution was evaluated in total cell population during in vitro culture in five 
different samples; results indicated an increase up to 49.8  7.8% in Lgr5+/Msi-1+ 
cells within four weeks of culture (Fig. 18C).  
On the other hand, by analyzing the expression of other recognized CRC 
stemness markers such as CD133 and CD44, the co-expression of Lgr5 and Msi-1 
appeared a more specific feature for SC identification (Fig. 18D). In fact CD44, as 
well as CD133, seemed to be expressed not only by the population Lgr5
+
/Msi-1
+
 in 
toto but also by other cells in the sample; the percentage of CD44
+
 or CD133
+
 cells 
was higher than that of Lgr5
+
/Msi
+
 cells.  
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Figure 18. In vitro stemness marker expression 
(A) Cytofluorimetric analysis of Msi-1 and Lgr5 expression by metastatic cells after one 
week in low adhesion condition; one representative experiment is shown; (B) 
Cytofluorimetric analysis of Msi-1 and Lgr5 expression by PKH26-labelled cells expressing 
different intensities of PKH26 (PKH
neg
, PKH
low
 and PKH
high
) at the 3
rd
 week of culture. Msi-
1
+
/Lgr5
+
 cells were found within both PKH
high
 and PKH
low
 cell populations, whereas no Msi-
1
+
/Lgr5
+
 cells were detected in the PKH
neg
 subset. One representative experiment out of three 
consecutive is shown; (C) Kinetics of Msi-1 and Lgr5 expression by total cell population at 
the 1
st
, 2
nd
, 3
rd
 and 4
th
 week of culture. All Lgr5
+
 cells also co-expressed Msi-1, whereas a 
small fraction of Msi-1
+
 cells did not express Lgr5. One representative experiment out of 5 is 
shown; (D) Cytofluorimetric analysis of CD44, CD133 and Msi-1 expression by metastatic 
cells after one week in low adhesion condition; one representative experiment is shown. 
 
 
Once identified within PKH
pos
 cells a subset expressing the stemness markers 
Lgr5 and Msi-1, we evaluated their differentiative potential. PKH
pos
 cells, sorted 
from spheroids, were cultured in the presence of 10% FCS in uncoated plates. After 
one week the cells did not form spheroids, as they did in the absence of serum; on the 
contrary, PKH
pos
 cells started to proliferate and adhere to the plate assuming an 
epithelial morphology, as shown by phase-contrast microscopy (Fig. 19A). 
Cytofluorimetric analysis revealed that these cells lost Msi-1 (not shown) and Lgr5 
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expression after 14 days of culture in the presence of serum (Fig. 19B) while they 
acquired the expression of CK20, a recognized marker of differentiation. 
 
 
Figure 19. In vitro Differentiation of Cultured PKH
pos
 Cells 
(A) Spheroids obtained from PKH
pos
 cells maintained in serum-free medium in non-adherent 
plates were dissociated, cells were FACS-sorted and PKH
pos
 cells were cultured in the 
presence of 10% FCS in adherent plates. The cells assumed an epithelial morphology as 
demonstrated by Crystal Violet staining; (B) Cytofluorimetric analysis of Lgr5 and Ck20 
expression in PKH
pos
 cells after 2 weeks in serum-free condition (left panel) or in 
differentiation condition (right panel). One representative experiment out of three is shown; 
the grey colored peak in each histogram represents the istotype control and the empty black 
peak refers to stained cells. 
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3. MUSASHI-1 REGULATION BY THE NOTCH PATHWAY 
 
3.1 DLL4 up-regulates Msi-1 transcript levels in CRC cells by a Notch2/3-
mediated mechanism  
Initially, we aimed at setting-up conditions for ligand-mediated stimulation of 
Notch signaling in CRC cells. To this end, MICOL-14
tum
 cells, transfected with a 
CSL-luc plasmid encoding the luciferase gene under the control of a Notch-
responsive promoter, were stimulated by hDLL4. Seventy-two hours later, Notch 
activity was measured by in vitro luciferase assay. We observed an 8-fold increase 
in luciferase activity in hDLL4-stimulated cells, compared to basal levels (Fig. 20 
A). Importantly, these effects were largely blocked by α-Notch2/3 but not α-Notch1 
mAbs (Fig. 20A), suggesting that DLL4 stimulation triggers Notch signaling 
through Notch2 and/or Notch3 receptors in MICOL-14
tum
 cells, which express 
Notch1-3 but lack Notch4 [103]. These data were supported by measurement of 
endogenous components of the Notch pathway by qRT-PCR. Indeed, in 5 
independent experiments, stimulation of MICOL-14
tum
 cells with hDLL4 
significantly increased both Notch3 and Hey-2 transcript levels, and this effect was 
blocked by -Notch2/3 mAb (Fig. 20B). Similar effects were also observed in 
primary cultures derived from CRC metastases (n=4). Indeed, Notch-3 and Hey-2 
transcript levels were significantly increased after hDLL4 stimulation and markedly 
decreased in the presence of -Notch2/3 (Fig. 20C). At variance with MICOL-14tum 
cells, incubation of primary tumor cells with -Notch2/3 significantly reduced 
levels of all Notch-related transcripts tested (including Notch1-3, Hey-1 and Hey-2) 
also in the absence of hDLL4 stimulation. 
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Figure 20. Notch pathway modulation by Ab -Notch2/3  
A) MICOL-14
tum
 cells transfected with the CSL-luc plasmid were stimulated for 72 h by 
recombinant human DLL4 (hDLL4). Notch activity was significantly blocked by -
Notch2/3 but not by -Notch1. Data are expressed as mean ± SD of three independent 
experiments; B) Measurements by qRT-PCR of expression levels of Notch pathway 
components (Notch1-3, Hes-1, Hey-2) after 72 h of stimulation with hDLL4 in MICOL-
14
tum
 cells. Data are expressed as mean ± SD of five different experiments; *p<0.05; C) 
Measurements by qRT-PCR of expression levels of Notch pathway components (Notch1-3, 
Hes-1, Hey-2) after 72 h of stimulation with hDLL4 in primary cultures from CRC liver 
metastases. Data are expressed as mean ± SD of four different experiments; *p<0.05.  
 
Next, we investigated effects of DLL4 stimulation on the expression of stem 
cell-associated and differentiation markers. We observed that recombinant hDLL4 
induced a 2-3-fold increase in Msi-1 levels in MICOL-14
tum
 cells, and this effect 
was largely blocked by -Notch2/3 treatment. We also observed increased levels of 
Muc-1 mRNA following Notch2/3 blockade in all cultures analyzed (Fig. 21A). 
Since Muc-1 is a marker of colon epithelial cells differentiation, this finding could 
indicate that neutralization of Notch2/3 promotes cell differentiation. In contrast, 
only marginal changes in Muc-2 and Numb transcripts were detected in these 
experiments either in the presence or the absence of hDLL4 (Fig. 21A). Up-
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regulation of Msi-1 levels was also observed following retroviral vector-mediated 
delivery of human DLL4 cDNA in MICOL-14
tum
 cells (Fig. 21B), thus confirming 
results obtained with recombinant hDLL4. To test whether the effect of hDLL4 was 
restricted to Msi-1 expression, we addressed the mRNA levels of several stem-
associated genes in MICOL-14
tum
 cells after 72h of hDLL4 stimulation. As reported 
in Figure 21C, DLL4 stimulation significantly influenced Msi-1 expression, 
whereas Bmi-1, EpCAM and EpHB2 mRNA levels did not show any change, and 
ALDH expression only showed a marginal non significant increased. 
HDLL4 induced a significant (p<0.05) increase of Msi-1 levels and a 
corresponding decrease in Muc-1 levels also in primary cultures derived from liver 
CRC metastases (Fig. 21D), and these modulations were completely blocked by -
Notch2/3. In primary tumor cultures, -Notch2/3 caused significant reduction of 
Msi-1 expression and concomitant increase of Muc-1 levels also in the absence of 
recombinant hDLL4 stimulation (Fig. 21D), probably reflecting higher endogenous 
levels of Notch signaling compared to MICOL-14
tum
 cells. 
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Figure 21. DLL4-mediated increase of Msi-1 levels in CRC cells is blocked by -
Notch2/3 antibody  
A) qRT-PCR analysis of stemness-associated genes after 72h of stimulation with α-
Notch2/3 or hDLL4 in MICOL-14
tum
 cells. Data are expressed as mean ± SD of five 
different experiments; *p<0.05; B) qRT-PCR after transfection of MICOL-14tum cells with 
hDLL4 or the control vector (CTRL-EGFP). Msi-1, Notch3 as well as Hey-2 significantly 
increased while no alteration in Numb RNA levels were detected, comparing with control 
vector or no treated cells (wild type, WT). Data are expressed as mean mean ± SD of three 
different replicates; *p<0.05; C)qRT-PCR of stemness markers after 72h of stimulation 
with hDLL4 in MICOL-14
tum
 cells; Msi-1 is the only marker significantly increase after 
treatment; data are expressed as mean ± SD of four different experiments; *p<0.05; D) 
Measurements by qRT-PCR of stemness-associated genes after 72h of stimulation with α-
Notch2/3 or hDLL4 in in primary cultures from CRC liver metastases. Data are expressed 
as mean ± SD of four different experiments; *p<0.05; 
 
3.2 Effects of Notch2/3 blockade on Msi-1 and Numb levels in CRC cells 
To validate these findings, we investigated the protein levels of Msi-1 in 
primary cultures of liver CRC metastases (n=5) by flow cytometry. Results 
indicated that hDLL4 increased until 18±4% Msi-1 expressing cells in tumor 
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samples. Moreover, α-Notch2/3 mAb strongly reduced (3.7±2.2%) the percentage 
of Msi-1
+
 cells both in hDLL4-stimulated and control cell cultures (Fig. 22A-B). 
Treatment with α-Notch1, conversely, had minimal effects on Msi-1 expression 
(Fig. 22A). 
 Immunofluorescence analysis confirmed that hDLL4 stimulation increased 
Msi-1 expression in MICOL-14
tum
 cells, and this effect was blocked by α-Notch2/3 
mAb (Fig. 22C). In contrast, the expression levels of CK18, a common epithelial 
marker for colon cancer cells, were not affected by these treatments (Fig. 22C). 
Notably, α-Notch2/3 treatment markedly reduced Msi-1 protein levels also in the 
absence of hDLL4 stimulation (Fig. 22A-C), exceeding variations in Msi-1 
transcript levels under the same experimental conditions (see Fig. 21A). 
Finally, we analyzed reciprocal effects of hDLL4 stimulation and α-Notch2/3 
blockade on Numb protein levels. We found that hDLL4 stimulation was associated 
with a small decrease in Numb protein levels and that α-Notch2/3 clearly increased 
Numb protein both in control and hDLL4-stimulated MICOL-14
tum
 and primary 
tumor cell cultures (Fig. 22D).  
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Figure 22. Effects of hDLL4 and α-Notch2/3 on Msi-1 protein levels in CRC cells. 
A) Flow cytometry analysis of Msi-1 expression in primary cultures from liver CRC 
metastases cultivated for 72h in hDLL4-coated wells (or BSA as control) in the presence or 
the absence of α-Notch2/3, α-Notch1, or control (CTRL) mAb. Data are expressed as mean 
± SD of percentage of Msi-1
+
 cells from five different experiments for α-Notch2/3 or 
hDLL4 and three different experiments for α-Notch1, *p<0.05; B) Representative analysis 
of Msi-1 expression in a primary sample: hDLL4 stimulation increased Msi-1 expression 
and this effect was completely blocked by α-Notch2/3. Gate are fixed on the isotype control 
and values indicate the percentage of Msi-1
+
 cells; C) Immunofluorescence analysis of 
MICOL-14
tum
 cells treated for 72h with α-Notch2/3, hDLL4, the combination of the two or 
with the corresponding control; nuclei were stained with TOPRO-3; magnification 40x; D) 
Western Blot analysis of Msi-1 and Numb protein with the control housekeeping tubulin. 
Protein lysates were obtained from MICOL-14
tum
 and primary cultures from liver 
metastases after treatment with α-Notch2/3, hDLL4, the combination of α-Notch2/3 and 
hDLL4 or the control BSA. The panels show one representative Western Blot out of three 
analyzed. 
 
3.3 Effects of Notch2/3 blockade on spheroid-forming cells 
As outlined above, Msi-1 is a well-recognized colon stem cell marker and one of 
the canonical features of cancer stem cells is their ability to form spheroids in vitro 
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under specific culture conditions. Based on these premises, we wondered whether 
Msi-1 reduction could lower the number of spheroid-forming cells. To test this 
hypothesis, we performed extreme limiting dilution assay (ELDA) with primary 
tumor cultures and MICOL-14
tum 
cells in the presence or absence of -Notch2/3. 
After four days, the frequency of spheroid-forming cells was significantly 
reduced by incubation with -Notch2/3 antibody to 1/738 (upper 1/1046, lower 
1/521), compared to the frequency recorded in the presence of a control antibody 
(1/239, upper 1/341 and lowe1/168) (Table 6). Similar results were obtained for 
MICOL-14
tum
 cells: the spheroid-forming cell frequency decreased from 1/142 
(1/341- 1/168) to 1/428 (1/614-1/298) in the presence of -Notch2/3 antibody 
(Table 6). These results indicate that attenuation of Msi-1 levels, associated with 
Notch2/3 blockade, could affect cancer stem cell features. 
 
 
Table 6. -Notch2/3 reduced spheroid forming ability 
Extreme limiting dilution analysis on MICOL-14
tum
 and primary samples incubated, at 
different concentrations as indicate in the table, for four days with α-Notch2/3 or CTRL 
antibody. Data were analyzed by a specific web-toll and the spheroids forming frequency 
represents a mean between the upper and lower results.  
 
3.4 Msi-1 modulation is Notch3-dependent 
These results seemed to indicate that blockade of either Notch2 or Notch3 
activation perturbs Msi-1 levels in CRC cells. To determine which Notch paralog 
was mainly involved in this effect, we overexpressed either Notch3 or Notch2 
intracellular domain (ICD) in MICOL-14
tum
 cells using retroviral vectors. We found 
that N3ICD overexpression induced a 3-fold increase in Msi-1 levels, together with 
Number of 
cells/well 
Number of 
well plated 
Number of well showing spheroids 
Human metastases                           MICOL14
tum
 
  CTRL -Notch2/3 CTRL -Notch2/3 
2000 30 30 27 30 29 
400 30 22 13 23 15 
80 30 10 4 17 11 
16 30 5 2 13 3 
Frequency                                       1/239                1/738                1/142              1/428 
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up-modulation of Notch3 and Hey2 levels (Fig. 23A). In contrast, expression of 
N2ICD increased Hey-2 mRNA levels but caused minimal variations of Msi-1 
mRNA levels (Fig. 23B). These results indicate that hDLL4 up-regulates Msi-1 
primarily by a Notch3-mediated mechanism.  
To corroborate the hypothesis that Notch-3 regulates Msi-1, Msi-1 expression 
was investigated in tumor xenografts formed by MICOL-14
tum
 cells transduced by a 
lentiviral vector encoding a Notch3-specific shRNA (sh235); as reported in our 
previous study [89], these cells show a 60-80% decrease in Notch3 mRNA levels, 
compared to control shRNA cells. Immunohistochemical analysis demonstrated 
very low Msi-1 expression in tumors bearing low Notch3 levels (Fig. 23C), in line 
with the hypothesis that Notch3 has a key role in tuning Msi-1 levels in these cells. 
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Figure 23. Notch3 contributed to regulation of Msi-1 levels in CRC cells 
A) qRT-PCR after transfection of MICOLO-14
tum
 cells with Notch3 ICD (CEGN3) or the 
control vector (CEG). Msi-1, Notch3 as well as Hey-2, significantly increased while no 
alteration in Numb RNA levels were detected, comparing with control vector or no treated 
cells (wild type, WT). Data are expressed as mean ± SD of three different replicates; 
*p<0.05; B) qRT-PCR after transfection of MICOLO-14
tum
 cells with a vector encoding 
Notch2 ICD (RV1-2) or the empty vector (RV5). Only Notch2ICD and the target gene Hey-
2 significantly increased. Overexpression of N2ICD did not affect Mis-1 levels comparing 
with control vector or no treated cells (wild type, WT). Data are expressed as mean ± SD of 
three different replicates; *p<0.05; C) Immonohistochemical analysis of Msi-1 expression 
on xenografts obtained by MICOL-14
tum
 cells transducted with a lentiviral vector (sh235) 
inducing a reduction of Notch3 mRNA levels or an empty vector (shRNA). Four different 
tumors were stained. 
 
3.4 Effect of Notch3 modulation on Notch1 protein 
Since Numb is a commonly recognized negative regulator of Notch1 [64], and 
Notch3 alteration induced modulation in Msi-1 protein that inhibits Numb, we 
analyzed whether also Notch1 could be influenced by Notch3 modulation. As 
expected, 72 h of stimulation with hDLL4 induced an increase of nuclear Notch1 
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activated form (N1ICD) in MICOL-14
tum 
cells (Fig. 24A) detected by 
immunofluorescence analysis. Furthermore, Western Blot analysis demonstrated 
that MICOL-14
tum
 cells transfected with a vector encoding for DLL4 showed an 
increase in N1ICD protein compared to the empty control vector (Fig. 24B); 
interestingly, the increase in N1ICD was also observed when MICOL-14
tum
 cells 
were transfected with a vector overexpressing Notch3 ICD (Fig. 24B), thus 
indicating a modulation in N1ICD induced by Notch3 alteration.  
 
 
 
Figure 24. Notch 3 overexpression increased Notch1 ICD 
A) Immunofluorescence of N1 activated domain (N1ICD) on MICOL-14
tum
 cells stimulated 
with hDLL4 for 72 h or BSA as control; hDLL4 increased the activation and transmigration 
of N1ICD into the nucleus (blu), one representative experiment is shown, magnification 
40x; B) Western Blot analysis of N1ICD with the control housekeeping -tubulin. Protein 
lysates were obtained from MICOL-14
tum
 cells transfected with a vector encoding DLL4, an 
empty control vector (CTRL), a vector overexpressing N3 (CEGN3) and the corresponding 
control (CEG). The panels show one representative Western blot. 
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DISCUSSION 
Our study demonstrated that the ability to form spheroids in serum-free medium 
is not restricted to tumor and pre-cancerous samples [94, 95], but that epithelial cells 
isolated from normal colon biopsies and maintained in stem cell medium are also 
able to form spheroidal structures, morphologically comparable to those obtained 
from tumor colon samples. This ability was confined to a slowly cycling PKH
pos
 
population, which survived in vitro in the absence of serum for up to 40 days. 
Indeed, after 6 weeks of culture the surviving population accounted for less than 5% 
of the input population; these cells, however, maintained a bright PKH26 staining. 
When transferred to a serum-containing medium, these cells underwent 
differentiation, as judged by the acquisition of adhesive properties, a different 
morphology, the loss of stemness markers, and the expression of typical 
differentiation markers such as CK20 and Muc-1/2.  
The major achievement of our work is the in vitro culture and characterization of 
several discrete cell populations, some of which endowed with more prominent stem-
like properties. In this regard, we focused our attention on two commonly recognized 
markers of colon stem cells, such as Msi-1 and Lgr5. Msi-1 is a RNA-binding 
protein that plays an essential role in regulating asymmetric cell division, by 
maintaining colon stem/progenitor cell proliferation and inhibiting the differentiation 
process [104]; Lgr5 is supposed to be a Wnt target gene, and its expression is lost as 
a consequence of the inhibition of the Wnt pathway [24]. Msi-1 and Lgr5 expression 
was evaluated in PKH
high
, PKH
low
 and PKH
neg
 cell subsets, as representative of cell 
populations which underwent increasing cycles of replication. Cytofluorimetric 
analysis showed that Lgr5 expression was strictly confined to the PKH
high
 subset, and 
all Lgr5
+
 cells also expressed Msi-1. On the contrary, even though Msi-1 was mainly 
expressed by PKH
high
 cells, not all Msi-1
+
 cells also expressed Lgr5, and a small 
proportion of Msi-1
+
 cells could also be found within PKH
low
 cells. In addition, while 
no co-expression of CK20 and Lgr5 could be documented, we identified a small 
subset of Msi-1
+
 cells which also expressed the differentiation marker CK20. Thus, 
based on PKH26 staining and stemness/differentiation marker expression, a 
hierarchy of several distinct populations could be defined in our in vitro cultures: I) a 
PKH
high
/Lgr5
+
/Msi-1
+
/CK20
-
 subset, which likely reflects a relatively quiescent 
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stem-like population that did undergo minimal in vitro proliferation; II) a 
PKH
high
/Lgr5
-
/Msi-1
+
/CK20
+
 population that did undergo poor proliferation but 
expressed a differentiation marker; III) a PKH
low
/Lgr5
-
/Msi-1
+
/CK20
-
 subset, where 
part of the cells which underwent active replication still maintained the expression of 
a stemness marker; IV) a PKH
low
/Lgr5
-
/Msi-1
-
/CK20
+
 subset; and V) a PKH
neg
/Lgr5
-
/Msi-1
-
 subset.  
The location of the two small “transitional” subsets (PKHhigh/Lgr5-/Msi-
1
+
/CK20
+
 cells and PKH
low
/Lgr5
-
/Msi-1
+
/CK20
-
 cells) within the developmental tree 
of colon epithelial cells is unclear. While both had lost the expression of one of the 
mostly recognized stemness markers, the former likely underwent poor replication 
(in view of its high PKH26 staining) and continued to express Msi-1 but in 
combination with a differentiation marker; the second subset (PKH
low
/Lgr5
-
/Msi-
1
+
/CK20
-
) instead, while continuing to express some properties of immature cells, 
underwent proliferation without acquiring a differentiated phenotype. To our mind, 
the apparently contrasting properties of PKH
high
/Lgr5
-
/Msi-1
+
/CK20
+
 cells, which 
also express markers typical of goblet cells (Fig. 3), could reflect a sort of 
“committed” subset [105], where the relatively immature cells quickly acquire the 
expression of classical differentiation markers (such as CK20 and Muc-1/2), without 
showing a significant proliferative potential, as demonstrated by the maintenance of 
high levels of PKH26 staining. On the other hand, PKH
low
/Lgr5
-
/Msi-1
+
/CK20
-
 cells 
might represent the natural evolution of a rapidly cycling immature reservoir, which 
did not acquire differentiation markers but also did not completely loose self-
maintaining properties. Within the limits of an analysis carried out in cells 
maintained in vitro in experimental, non-physiologic conditions, our observations 
might reconcile the debate on the relative quiescence of stem-like cells in the 
gastrointestinal tract [106], by showing that cells with differential expression of 
commonly recognized stemness markers may coexist and show different replicative 
potential.  
Our phenotypic data are buttressed by the analysis of the transcriptomic profile of 
the above stemness/differentiation markers in PKH
neg
, PKH
low
 and PKH
high
 cells, 
compared to that observed in cells obtained by the microdissection of distinct crypt 
portions (Fig. 4B). The cells isolated at the very bottom of the crypt expressed huge 
amounts of mRNA for both Msi-1 and Lgr5; on the other hand, differentiated cells at 
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the very top of the crypts only showed high levels of CK20, and no Msi-1/Lgr5 
mRNA was detected. While these ex vivo results were not surprising, it is noteworthy 
that they fully mirrored the figures observed in the corresponding subsets expanded 
in culture (Fig. 4), further buttressing the notion that PKH
high
 cells do contain a cell 
population endowed with stem-like properties.  
The analysis of putative stemness markers in normal colon epithelial cells 
seemed to identify Lgr5 and Msi-1 expression as a prominent feature of stem-like 
cells. Thus, we concentrate our attention on these particular markers, and addressed 
their relationship with other membrane receptor which have been claimed to 
participate in the tumorigenesis process, such as the members of the Notch family. 
The presence of a slowly cycling cell population, expressing the stemness 
markers Msi-1 and Lgr5 and able to form spheroidal structure was thus analyzed in 
samples of CRC primary tumors and liver metastases. In tumor samples we could 
identify a PKH
high
 subset, persisting in in vitro culture for over five weeks, that 
mirrored the stem-like population found in normal samples. However, by analyzing 
the dye expression in the metastatic samples, we recorded the in vitro selection of a 
cell subset with intermediate PKH intensity: the PKH
low
 cells, while the PKH
high
 
subset, also present in the total cell population, progressively declined over the 
culture period. Both PKH
high
 and PKH
low
 populations expressed Lgr5 and Msi-1, 
were able to form spheroids in PhEMA-treated plate, and to differentiate in the 
presence of serum loosing Msi-1 and Lgr5 expression while acquiring CK20 
expression. These results seemed to indicate that in the metastatic samples the 
population endowed with stem-like features is not mainly confined to the non-
cycling subset. 
In the metastatic samples we focused our attention on Msi-1 expression. It is 
known that Msi-1 is a RNA-binding protein that acts to regulate Notch activation and 
migration to the nucleus, where it interacts with the DNA-binding protein CSL thus 
inducing transcription of specific target genes. Msi-1 protein, in fact, binds Numb 
mRNA thus inhibiting Numb-mediated degradation of Notch intracellular domain 
(ICD). Using a monoclonal antibody, we demonstrated that neutralization of 
Notch2/3 signaling affects Msi-1 levels in both the CRC cell line MICOL-14
tum
 and 
primary human samples. We observed an increase in mRNA and protein Msi-1 levels 
after stimulation with a common ligand of the Notch pathway (hDLL4); in parallel 
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we observed a reduction of both Notch3 and Msi-1 levels after incubation with -
Notch2/3 mAb. No reduction was detected after incubation with -Notch1. To 
understand whether Notch3 or Notch2 was involved, we performed qRT-PCR 
analysis of Msi-1 levels in MICOL-14
tum
 cells transfected with a vector 
overexpressing Notch2ICD or Notch3ICD: only N3ICD overexpression was 
associated with increase Msi-1 transcript levels. Moreover, 72 h of incubation with 
-Notch 2/3 mAb increased Muc-1 protein, whereas stimulation with hDLL4 was 
associated with reduction of Muc-1. Since Muc-1 is a marker of colon epithelial cells 
differentiation, this result could indicate that neutralization of Notch2/3 promotes cell 
escape from stemness condition to undergo differentiation, as also supposed by the 
decrease in Msi-1 expression, the increase in Muc-1 levels and the reduction in the 
spheroid-forming cell frequency after Notch3 blockade. 
Thus Notch3 appears to regulate Msi-1 expression at both protein and mRNA 
levels; as a consequence of this, we detected a modulation also in its target Numb 
and interestingly in Notch1ICD. It is known that Notch3 is a target of Notch1, but 
our results indicate for the first time a possible regulation of Notch1 by Notch3 
probably through Msi-1, by a mechanism involving degradation of Numb mRNA 
and blocking its destabilizing effects on Notch1ICD. It has previously been 
demonstrated [107] that Numb and its four isoforms differentially inhibit the Notch 
ICD: using a luciferase-reporter Beres and colleagues determined the ability of each 
Numb isoform to inhibit significantly Notch1ICD; in contrast Notch3ICD was not 
inhibited by any of the Numb isoforms [107].   
Based on the above findings and interpreting them with published data, we 
describe a novel feed-forward circuit of Msi-1, Numb, Notch3 and Notch1 
regulation, schematized in Figure 25. Further work will be needed, to clarify how 
Msi-1 modulation occurs. Since Notch3 is a well-established transcriptional factor, 
we will firstly investigate the possible transcriptional regulation of Msi-1 by Notch3. 
We have already performed a bioinformatic analysis of the distribution of canonical 
and non-canonical CSL binding domains in Msi-1 promoter region and compared it 
with Hes1 and Hey2, well recognized Notch target genes. We observed a similar 
expression and distribution of the CSL-binding domains in the genes analyzed but 
will be necessary to validate this prediction by further experimental work.  
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Figure 25. Schematic representation of a novel feed-forward circuit of Msi-1 
regulation. 
A) The Notch ligand DLL4 stimulates both Notch3 and Notch1; increase of Notch3 induces 
an increase of Msi-1 protein that binds Numb mRNA, thus repressing its inhibitory action 
effect Notch1. Activated Notch1 can migrate into the nucleus and induce the transcription of 
specific target genes such as Notch3; B) When Notch3 is inhibited, the reduced levels of 
Msi-1 don’t inhibit Numb mRNA, thus limiting Notch signaling including further induction 
of Notch3 expression. 
 
 76 
 
 77 
REFERENCES 
 
1. Verfaillie CM, Pera MF, Lansdorp PM et al. Stem cells: hype and reality. 
Hematology Am Soc Hematol Educ Program (2002); 369–391 
 
2. Weissman IL. Stem cells: units of development, units of regeneration, and 
units in evolution. Cell (2000); 100: 157–168 
 
3. Li L and Bhatia R. Stem cells quiescence. Clin Cancer Res (2011); 17: 4936- 
4941 
 
4. Barker N and Clevers. Leucine-Rich Repeat-Containing G-protein-coupled 
receptor as markers of adult stem cells. Gastroenterol (2010); 138: 1681-1696 
 
5. Schofield R. The relationship between the spleen colony-forming cell and the 
haemopoietic stem cell. Blood Cells (1978); 4: 7–25 
 
6. Li L, Xie T. Stem cell niche: structure and function. Annu Rev Cell Dev Biol 
(2005); 2:605–31 
 
7. Spradling A, Drummond-Barbosa D, Kai T. Stem cells find their niche. 
Nature (2001); 414: 98–104 
 
8. Tumbar T, Guasch G, Greco V et al. Defining the epithelial stem cell niche in 
skin. Science (2004); 303: 359–63 
 
9. He XC, Zhang J, Li L. Cellular and molecular regulation of hematopoietic 
and intestinal stem cell behavior. Ann N Y Acad Sci (2005); 1049: 28–38 
 
10. Sato T, Stange DE, Ferrante M, et al. Long-term expansion of epithelial 
organoids from human colon, adenoma, adenocarcinoma, and Barrett's 
epithelium. Gastroenterology (2001); 141: 1762-72 
 
11. Jung P, Sato T, Merlos-Suarez A et al. Isolation and in vitro expansion of 
human colonic stem cells. Nature Med (2011); 17: 1225-1227 
 
12. Booth C and Potten C. Gut instinct: thoughts on intestinal epithelial stem 
cells. J Clin Invest (2000); 105: 1493-1499 
 
13. Kumar V, Abbas AK, fausto N et al. Chapter 15. In Robbin's Basic Pathology 
(2007); 8th ed: 579-586 
 
14. Potten CS, Kellett M, Roberts SA et al. Measurement of in vivo proliferation 
in human colorectal mucosa using bromodeoxyuridine. Gut (1992); 33: 71-78 
 
15. Barker N, van de Wetering M and Clevers H. The intestinal stem cells.Genes 
Dev (2008);22: 1856-1864 
 
 78 
16. Zeki S, Graham T and Wright N. Stem cells and their implications for 
colorectal cancer. Gastroenterol Hepatol (2011); 8: 90-100 
 
17. Fujimoto K, Beauchamp RD, Whiteheal RH. Identification and isolation of 
candidate human colonic clonogenic cells based on cell surface integrin 
expression. Gastroenterology (2002); 123:1941–1948 
 
18. Sophos NA, Vasiliou V. Aldehyde dehydrogenase gene superfamily: the 
2002 update. Chem Biol Interact (2003);143–144:5–22.  
 
19. Huang EH, Hynes MJ, Zhang T, Ginestier C et al. Aldehyde dehydrogenase 1 
is a marker for normal and malignant human colonic stem cells (SC) and 
tracks SC overpopulation during colon tumorigenesis. Cancer research 
(2009); 69: 3382 
 
20. Khalek FJA, Gallicano GI and Mishra L. Colon cancer stem cells. 
Gastrointest Cancer Res Supll (2010); 1: 16-23 
 
21. Nishimura S, Wakabayashi N, Toyoda K et al Expression of Musashi-1 in 
Human Normal colon crypt cells. Digestive diseases and sciences (2003); 48: 
1523-1529 
 
22. May R, Riehl TE, Hunt C et al. Identification of a novel putative 
gastrointestinal stem cell and adenoma stem cell marker, doublecortin and 
CaM kinase-like-1, following radiation injury and in adenomatous polyposis 
coli/multiple intestinal neoplasia mice. Stem Cells (2008); 26: 630–637 
 
23. Sangiorgi E and Capecchi MR. Bmi1 is expressed in vivo in intestinal stem 
cells. Nature Genetics (2008); 40: 915-920  
 
24. Barker N, Van Es JH, Kuipers J et al. Identification of stem cells in small 
intestine and colon by marker gene Lgr5. Nature (2007): 449:1003-1007  
 
25. Barker N, Ridgway RA, Van ES JH et al. Crypt stem cells as the cells-of-
origin of ntestinal cancer. Nature Letters (2009); 457: 608-612. 
 
26. Nakamura M, Okano H, Blendy Aj and Montell C. Musashi, a neural RNA-
binding protein required for Drosophila adult external sensory organ 
development. Neuron (1994); 13:67-81 
 
27. Sugiyama-Nakagiri Y, Akiyama M, Shibata A et al. Expression of RNA-
binding Musashi in hair follicle development and hair cycle progression. Am 
J Pathol (2006); 168: 80-92 
 
28. Kayahara T, Sawada M, Takaishi S et al. Candidate markers for stem and 
early progenitor cells, Musashi-1 and Hes-, are expressed in crypt base 
columnar cells of mouse small intestine. FEBS Lett (3003); 535: 131-135 
 
 79 
29. Clarke RB, Spence K, Anderson E et al. A putative human breast stem cell 
population is enriched for sferoid receptor-positive cells. Dev Biol (2005); 
277: 443-456  
 
30. Okano H, Kawahara H, Toriya M et al. Function of RNA-binding protein 
Musashi-1 in stem cells. Exp Cell Res (2005); 306: 349-356 
 
31. Imai T, Tokunaga A, Yoshida T et al. The neural RNA-binding protein 
Musashi1 translationally regulates mammalian numb gene expression by 
interacting with its mRNA. Mol Cell Biol (2001); 21: 3888-3900 
 
32. Battelli C, Nikopopulos GN, Mitchell JG et al. The RNA-binding protein 
Musashi-1 regulates neural development through the translational repression 
of p21WAF-1. Mol Cell Neurosci (2006); 31: 85-96 
 
33. Horisawa K, Imai T, Okano H et al. 3'-Untranslated region of dublecortin 
mRNA is a binding target of the Musashi1 RNA-binding protein. FEBS Lett 
(2009); 583: 2429-2434 
 
34. Jordan CT, Guzman ML and Noble M. Cancer Stem cells. New England J 
Medicine (2006); 355: 1253-1261  
 
35. Moserle L, Ghisi M, Amadori A et al. Side population and cancer stem cells: 
therapeutic implications. Cancer Lett (2010); 288:1-9. 
 
36. Charafe-Jauffret E, Ginestier C, Iovino F et al. Breast cancer cell lines 
contain functional cancer stem cells with metastatic capacity and a distinct 
molecular signature. Cancer Res (2009); 69: 1302-1313. 
 
37. Fan X, Matsui W, Khaki L et al. Notch pathway inhibition depletes stem-like 
cells and blocks engraftment in embryonal brain tumors. Cancer Res (2006); 
66: 7445-7452  
 
38. Cicalese A, Bonizzi G, Pasi CE, et al. The tumor suppressor p53 regulates 
polarity of self-renewing divisions in mammary stem cells. Cell (2009); 138: 
1083-1095. 
 
39. Todaro M, Alea MP, Di Stefano AB et al. Colon cancer stem cells dictate 
tumor growth and resist cell death by production of interleukin-4. Cell Stem 
Cell (2007); 1: 389-40  
 
40. Hirschmann-Jax C, Foster AE, Wulf GG, et al. A distinct "side population" of 
cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci 
U S A (2004); 10: 14228-14233. 
 
41. Moitra K, Lou H et Dean M. Multidrug efflux pumps and cancer stem cells: 
insights into multidrug resistance and therapeutic development. Clin 
Pharmacol Ther (2011); 89: 491-502 
 
 80 
42. Ricci-Vitiani L, Lombardi DG, Pilozzi E et al. Identification and expansion 
of colon-cancer-initiating cells. Nature (2007); 445:111-115 
 
43. O'Brien CA, Pollett A, Gallinger S et al. A human colon cancer cell capable 
of initiating tumor growth in immunodeficient mice. Nature (2007); 445:106-
110  
 
44. Shmelkov SV, Butler JM, Hooper AT, et al. CD133 expression is not 
restricted to stem cells, and both CD133
+
 and CD133
-
metastatic colon cancer 
cells initiate tumors. J Clin Invest (2008); 118: 2111–2120. 
 
45. Dalerba P, Dylla SJ, Park IK et al. Phenotypic characterization of human 
colon cancer stem cells. Proc Natl Acad Sci USA (2007); 104: 10158-10163 
 
46. Todaro M, Perez A, Scopelliti JP et al. IL-4 mediated drug resistance in colon 
cancer stem cells. Cell Cycle (2008); 7: 309-313 
 
47. Vermuelen L, Todaro M, de Sousa Mello et al. Single-cell cloning of colon 
cancer stem cells reveals a multi-lineage differentiation capacity. Proc Natl 
Acad Sci USA (2008); 105: 13427-13432 
 
48. Huang EH, Hynes MJ, Zhang T et al. Aldehyde dehydrogenase 1 is a marker 
for normal and malignant human colonic stem cells (SC) and tracks SC 
overpopulation during colon tumorigenesis. Cancer Res (2009); 69: 3382-
3389 
 
49. Muraro MG, Mele V, Daster S et al. CD133+,CD166+CD44+, and 
CD24
+
CD44
+
 phenotypes fail to reliably identify cell population with cancer 
stem functional features in established human colorectal cancer cell line. Stem 
Cell Transl Med (2012); 1: 592-603 
 
50. Jemal A, Siegel R Xu J et al. Cancer statistics, 2010. Cancer J Clin (2011); 6: 
133-134 
 
51. Frank SA. Dynamics of cancer: incidence, inheritance and evolution. 
Princeton (NJ): princeton University press (2007); Chapter 3 
 
52. Ionov Y, Peinado MA, Malkhosyan S et al. Ubiquitous somatic mutations in 
simple repeated sequences reveal a new mechanism for colon carcinogenesis. 
Nature (1993); 363: 558-561 
 
53. Rizk P and Barker N. Gut stem cells in tissue renewal and disease: methods, 
markers and myths. WIREs Syst Biol Med (2012); 4: 475-496 
 
54. Liotta  LA, Kohn EC. Cancer's deadly signature. Nat Genet (2003); 33: 10-11 
 
55. Kessenbrock K, Plaks V and Werb Z. Matrix metalloproteinases: regulators 
of the tumor microenvironment. Cell (2010); 141: 52-67 
 
 81 
56. Thompson EW and Haviv I. The social aspect of EMT-MET plasticity. 
Nature Med (2011); 17: 1048-1049 
 
57. Wharton KA, Johansen KM, Xu t et al. Nucleotide sequence from the 
neurogenic locus notch implies a gene product that share homology with 
proteins containing EGF-like repeats. Cell (1985); 43: 567-581 
 
58. Fiuza UM and Arias AM. Cell and molecular biology of Notch. J Endocrinol 
(2007); 194: 459-474 
 
59. Kopan R. Notch: a membrane-bound transcription factor. J Cell Sci (2002); 
115: 1095-1097 
 
60. D'Souza B, Miyamoto A and Weinmaster G. The many facets of Notch 
ligands. Oncogene (2008); 27: 5148-5167 
 
61. Thurston G, Noguera-Troise I and Yancopoulos GD. The Delta paradox: 
DLL4 blockade leads to more tumour vessels but less tumour growth. Nat 
Rev Cancer (2007); 7: 327-331 
 
62. Wu L and Griffin JD. Modulation of Notch signaling by mastermind-like 
(MAML) transcriptional co-activators and their involvement in 
tumorigenesis. Semin Cancer Biol (2004); 14: 348-356  
 
63. Leon KG and Karsan A. Recent insights into the role of Notch signaling in 
tumorigenesis. Blood (2006);107: 2223-2233 
 
64. Glazer RI, Wang XY, Yuan H et al. Musashi-1 a stem cell marker no longer 
in search of a function. Cell Cycle (2008); 7: 2635-2639 
 
65. Sander GR and Powell BC. Expression of notch receptors and ligands in the 
adult gut. J Histochem Cytochem (2004); 52: 509-516 
 
66. van Es JH, van Gijn ME, Riccio O et al. Notch/gamma-secretase inhibition 
turns proliferative cells in intestinal crypts and adenomas into goblet. Nature 
(2005); 435: 959-963 
 
67. Fre S, Huyghe M, Mourikis P et al. Notch signals control the fate of 
immature progenitor cells in the intestine. Nature (2005); 435: 964-968 
 
68. Riccio O, van Gijn ME, Bezdek AC et al. Loss of intestinal crypt progenitor 
cells owing to inactivation of both Notch1 and Notch2 is accompanied by 
derepression of CDK inhibitors p27Kip1 and p57Kip2. EMBO Rep (2008); 9: 
377-383 
 
69. Jensen J, Pedersen EE, Galante P et al. Control of endodermal endocrine 
development by Hes-1. Nat Genet (2000); 24: 36-44  
 
 82 
70. Suzuki K, Fukui H, Kayahara T et al. Hes1-deficien mice show precious 
differentiation of Paneth cells in the small intestine. Biochem Biophys Res 
Commun (2005);328: 348-352 
 
71. Jenny M, Uhl C, Roche C et al. Neurogenin3 is differentially required for 
endocrine cell fate specification in the intestinal and gastric epithelum EMBO 
J (2002); 21: 6338-6347 
 
72. Ng AY, Waring P, Ristevski S et al. Inactivation of the transcription factor 
Elf3 in mice results in dysmorphogenesis and altered differentiation of 
intestinal epithelium Gastroenterology (2002); 122:1455-1466 
 
73. van der Flier LG and Clevers H. Stem cells, self-renewal, and differentiation 
in the intestinal epithelium. Annu Rev Physiol (2009); 71: 241-260 
 
74. Wang J, Wakeman TP, Lathia JD et al. Notch promotes radioresistance of 
glioma stem cells. Stem Cells (2010); 28:17-28  
 
75. Farnie G and Clarke RB. Mammary stem cells and breast cancer-role of 
Notch signalling. Stem Cell Rev (2007); 3: 169-175 
 
76. Katoh, M. Notch signaling in gastrointestinal tract (review). Int J Oncol 
(2007); 30: 247-251 
 
77. Ji Q, Hao X, Zhang M et al. MicroRNA miR-34 inhibits human pancreatic 
cancer tumor-initiating cells. PLoS One (2009); 4: e6816 
 
78. Zhang T, Otevrel T, Gao Z et al. Evidence that APC regulates survivin 
expression: a possible mechanism contributing to the stem cell origin of colon 
cancer. Cancer Res (2001); 61: 8664-8667 
 
79. Ulasov IV, Nandi S, Dey M et al. Inhibition of Sonic hedgehog and Notch 
pathways enhances sensitivity of CD133(+) glioma stem cells to 
temozolomide therapy. Mol Med (2011); 17: 103-112 
 
80. Fan X, Matsui W, Khaki L et al. Notch pathway inhibition depletes stem-like 
cells and blocks engraftment in embryonal brain tumors. Cancer Res (2006); 
66: 7445-7452 
 
81. Hoey T, Yen WC, Axelrod F et al. DLL4 blockade inhibits tumor growth and 
reduces tumor-initiating cell frequency. Cell Stem Cell (2009); 5: 168-177 
 
82. Dontu G, Jackson KW, McNicholas E et al. Role of Notch signaling in cell-
fate determination of human mammary stem/progenitor cells. Breast Cancer 
Res (2004); 6: R605-615 
 
83. Serafin V, Persano L, Moserle L et al. Notch3 signaling promotes tumor 
growth in colorectal cancer. J Pathol (2011); 224: 448-460 
 
 83 
84. Todaro M, Alea MP, Di Stefano AB et al. Colon cancer stem cells dictate 
tumor growth and resist cell death by production of interleukin-4. Cell Stem 
Cell (2007); 1: 389-402. 
 
85. Dalerba P, Guiducci C, Poliani PL et al. Reconstitution of human telomerase 
reverse transcriptase expression rescues colorectal carcinoma cells from in 
vitro senescence: evidence against immortality as a constitutive trait of tumor 
cells. Caner Res (2005); 65: 2321-2329 
 
86. Indraccolo S, Minuzzo S, Masiero M et al. Cross-talk between tumor and 
endothelial cells involving the Notch3-Dll4 interaction marks escape from 
tumor dormancy. Cancer Res (2009); 69: 1314-1323 
 
87. Cicalese A, Bonizzi G, Pasi CE et al.The tumor suppressor p53 regulates 
polarity of self-renewing divisions in mammary stem cells. Cell (2009); 138: 
1083-1095  
 
88. Moserle L, Ghisi M, Amadori A and Indraccolo S. Side population and 
cancer stem cells: therapeutic implication. Cancer Lett (2010); 288: 1-9. 
 
89. Weng AP, Ferrando AA, Lee W et al. Activating mutations of NOTCH1 in 
human T cell acute lymphoblastic leukemia. Science (2004); 306: 269-271 
 
90. Ghisi M, Corradin A, Basso K et al. Modulation of microRNA expression in 
human T-cell development: targeting of NOTCH3 by miR-150. Blood 
(2011); 117: 7053-7062 
 
91. Williams CK, Li JL, Murga M, Harris AL et al. Up-regulation of Notch 
ligand Delta-like 4 inhibits VEGF-induced endothelial cell function. Blood 
(2006); 107: 931-939 
 
92. Indraccolo S, Habeler W, Tisato V, et al. Gene transfer in ovarian cancer 
cells: a comparison between retroviral and lentiviral vectors. Cancer Res 
(2002); 62: 6099–107  
 
93. Lanzkron S, Collector M, Sharkis SJ. Hematopoietic stem cell tracking in 
vivo: a comparison of short-term and long-term repopulating cells. Blood 
(1999); 93: 1916-1921.  
 
94. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumors: accumulating 
evidence and unresolving questions. Nature review (2008); 8: 755-767. 
 
95. Morrison JB, Schmidt CW, Lakhani SR et al. Breast cancer stem cells: 
implications for therapy of breast cancer. Breast Cancer Res (2008); 10: 210. 
 
96. Sato T, Vries RG, Snippert HJ et al. Single Lgr5 stem cells build crypt-villus 
structures in vitro without a mesenchymal niche. Nature (2009); 459: 262-
265. 
 
 84 
97. Takeda K, Kinoshita I, Shimizu Y et al. Expression of LGR5, an intestinal 
stem cell marker, during each stage of colorectal tumorigenesis. Anticancer 
Res (2011); 31: 260-270 
 
98. Humphries A, Wright N. Colonic crypt organization and tumorigenesis. Nat 
Rev Cancer (2008); 8: 415-424 
 
99. Roig AI, Eskiocak U, Hight SK et al. Immortalized epithelial cells derived 
from human colon biopsies express stem cell markers and differentiation in 
vitro. Gastroenterology (2010); 138: 1012-1021. 
 
100. Schulenburg A, Cech P, Herbacek I et al. CD44-positive colorectal adenoma 
cells express the potential stem cells markers musashi antigen (msi1) and 
ephrin B2 receptor (EphB2). J Pathol (2007); 213: 152-160 
 
101. Huang EH, Hynes MJ, Zhang T et al. Aldehyde dehydrogenase 1 is a marker 
for normal and malignant human colonic stem cells (SC) and tracks SC 
overpopulation during colon tumorigenesis. Cancer Res (2009); 69: 3382-
3389 
 
102. Dalerba P, Kalisky T, Sahoo D et al. Single-cell dissection of transcriptional 
heterogeneity in human colon tumors. Nature Biothecnol (2011); 29: 1120-
1127. 
 
103. Gopalakrishnan N, Jayanthi V and Devaraj H. c-kit and Musashi-1 
expression in colorectal carcinoma and its association with etiological 
factora. Oncol Gastroenterol Hepatol Reports (2012); 1:25-32 
 
104. MacNicol A, Wilczynska A, MacNicol M. Function and regulation of the 
mammalian Musashi mRNA translational regulator. Biochem Soc Trans 
(2008); 36: 528-530.  
 
105. Dangles-Marie V, Validire P, Richon S et al. Isolation and characterization of 
spontaneous spheroid aggregates within human colon carcinomas. J Clin 
Oncol (2007); 25: 14515 
 
106. Shaker A, Rubin DC. Intestinal stem cells and epithelial-mesenchymal 
interactions in the crypt and stem cell niche. Transl Res (2010); 156: 180-187. 
 
107. Beres BJ, George R, Laugher E et al. Numb regulates Notch1, but not 
Notch3, during myogenesis. Mech Dev (2011); 128: 247-257 
 
 
 
 
 
 
 
 
 85 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
